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       Science may set limits to knowledge, 
       but should not set limits to imagination. 
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 1 Introduction 
 
1.1 Gene therapy 
 
Gene therapy is a promising pharmaceutical research field dealing with the insertion of 
nucleic acids into cells and tissues of an organism to treat neoplastic, metabolic and 
hereditary diseases[1][2][3]. The nucleic acids used in gene therapy are mostly parts of 
genes encoding normal versions of mutated, defective or missing proteins responsible 
for clinical manifestations of many diseases. The insertion and substitution of 
pathologically altered genes with their normal alternative is the main purpose of this 
new therapeutic approach. Another possibility is to regulate gene expression on the 
level of messenger RNA, e.g. by siRNA technology[4][5]. Both approaches need reliable 
nucleic acid carrier systems which protect the nucleic acids against enzymatic 
degradation by nucleases and deliver them to the target cells without spreading them 
to non-target tissues. Designing and testing efficient gene delivering devices is then an 
essential step in the development of gene therapy strategies. 
 
 
1.2 Viral vectors 
 
The utilization of viral vectors has been representing an efficient gene delivery device 
for many years. Viruses seem to be very effective thanks to powerful mechanisms of 
entering the host’s target cells and delivering genetic material into their nuclei[6][7]. 
Many different viral types have been tested for gene delivery into mammalian 
organisms. However the viral interaction with the host immune system may cause 
adverse effects. Neutralizing antibodies may recognize and eliminate viruses causing 
inflammatory reactions; cells infected by a virus can be recognized as not self by the 
host immune system and eliminated; moreover the presence of viral genome within an 
organism might lead to severe immune response with adverse effects for the host 
itself. A further undesirable consequence of virus-mediated transfections is the 
integration of parts of the viral genome into the host’s one with possible activation of 
oncogenes[8]. Adenoviruses[9] for example, a family of DNA viruses, show high-rate of 
gene delivery but most transfected cells are rapidly removed by the immune 
system[10]. Herpes simplex virus can deliver large amounts of exogenous DNA as well 
but cytotoxicity and maintenance of transgene expression remain obstacles[11] in its 
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application. Other limiting factors are high costs and procedure complexity. 
 
 
1.3 Non-viral vectors 
 
Non-viral vectors are the alternative to viruses in gene therapy studies because of 
many favorable characteristics like large-scale production and low immunogenicity. 
The first experiments using non-viral gene therapy technologies however showed low 
levels of transfection while general opinion was that viral vectors are more effective 
despite their many adverse effects. However recent developments in non-viral gene 
delivery are displaying transfection efficiencies similar to viruses. 
The first and simplest approach to non-viral gene delivery is the application of naked 
plasmid DNA. Some successful results following intramuscular injection of plasmid DNA 
have been obtained but the transfection rate was very low. Anyway these experiences 
contributed to the idea of “protecting” nucleic acids from damage. To this purpose 
new molecular aggregates, called lipoplexes and polyplexes, have been synthesized 
that protect DNA from degradation during the transfection processes. Plasmid DNA or 
siRNA can be bound to lipids in an organized structure which resembles a micelle or a 
liposome. Once this organized structure is complexed with DNA it is called a lipoplex. 
Cationic lipids naturally complex with negatively loaded DNA due to their positive 
charge. In the same way they can electrostatically interact with the cell membrane. As 
long as endocytosis of the lipoplex occurs, DNA is released into the cytoplasm. These 
cationic lipids also protect DNA from enzymatic degradation within the cytosol. The 
most popular application of lipoplexes has been gene transfer into cancer cells. Some 
studies have shown lipoplexes to be useful in transfecting respiratory epithelial cells, 
so that they may be utilized in genetic respiratory diseases such as cystic fibrosis[12] as 
well as neoplasias[13]. 
Polycationic gene delivery systems, called polyplexes, are a very promising alternative 
to lipoplexes. They were at first based on polylysine and later on polyethylenimine 
(PEI). PEI was first described by the group of Jean-Paul Behr as gene delivering device 
for mammalian cells[14][15] and is at present the most utilized polycation. PEI contains 
repetitive ethylene imine groups (molecular formula: C2H5N) and is available in linear 
and branched form. Linear PEI (PEI lin) contains just secondary amines, in contrast to 
branched PEI (PEI br) which has primary, secondary and tertiary amino groups (fig. 1 
and 2). 
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Fig. 1: schematic structure of linear PEI. 
 
 H2N- (CH2-CH2-NH)x -NH2 
 
 
Fig. 2: schematic structure of branched PEI. 
 
PEI offers high positive charge density and intrinsic buffering capacity that allow good 
electrostatic binding to negatively charged nucleic acids and efficient compaction of 
them within the polyplexes. PEI-based polyplexes protect nucleic acids from 
degradation and enable interactions with negatively loaded cell surfaces triggering the 
uptake of themselves. PEI enters cells through adhesion to transmembrane heparan 
proteoglycans[16] and shows very good transfection capacity in vitro and in 
vivo[17][18][19]. Many authors
[20] recommend to protect PEI-based gene vectors with 
molecules masking their positive surfaces to prevent opsonization by the mononuclear 
phagocytic system and subsequent rapid clearance from circulation. Polyethylene 
glycol (PEG) is a hydrophilic molecule suited for this purpose. 
A considerable problem of PEI is its distinctive toxicity observed in vitro[21] and in 
vivo[22] and its unspecific interactions with body structures and fluids[23]. It can in fact 
interact with membrane-integrated and circulating proteins and is able to mediate 
erythrocytes aggregation[24] and activation of the endothelium particularly within the 
pulmonary circulation. These toxic properties increase with the density of positive 
charge and molecular weight of the polycationic chain. The neutralization of positively 
charged polymers by polyplex formation significantly reduces their toxicity. Besides the 
acute one the long-term toxicity might be a considerable factor conditioning the 
clinical applications of these carriers.  
Recently other polymers have been synthesized aiming to reduce the unfavorable 
acute effect of PEI injection. At the Chair of Pharmaceutical Biotechnology (LMU, 
Munich) oligoethylenimines (OEI) with low molecular weight cross-linked with 
degradable linker molecules were designed. The most promising product of this class 
of molecules was HD O, a OEI 800 Da core modified with hexane-1,6-diol diacrylate 
and surface-modified with OEI 800 Da (fig. 3). HD O shares with PEI targeting tumor 
capacity and is better tolerated in vivo studies[25] likely owing to its smaller size and 
biodegradability. 
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Fig. 3: synthesis and schematic structure of HD O. 
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1.4  In-vivo imaging 
 
1.4.1 Imaging technologies and their in-vivo applications 
 
Several imaging devices have been developed to check in vivo pharmacodynamic and 
pharmacokinetic aspects of the interactions between gene carriers and somatic cells. 
This field has known considerable expansion thanks to well-established imaging 
technologies including magnetic resonance imaging (MRI), positron emission 
tomography (PET) and single photon emission tomography (SPECT). Bioluminescence 
and fluorescence-based labeling of vectors are other powerful strategies for gene 
delivery[26][27][28][29]. These optical imaging methods are often preferred to MRI and 
SPECT/PET because they can be performed both in vitro and in vivo studies with 
simpler study design and cheaper imaging set-ups.  
 
1.4.2 Bioluminescence 
 
Bioluminescence is the emission of light by a living organism as the result of enzymatic 
reactions. The enzyme luciferase is expressed in certain vertebrates and invertebrates 
and emits visible light by converting the respective substrate to the product. Firefly 
(Fluc) and Renilla (Rluc) luciferase genes are responsible for this enzymatic activity and 
can be transferred to other organisms included in plasmids. The genetic expression of 
these transgenes and their visible manifestation need luciferin as specific substrate and 
some co-substrates normally contained in cells possessing luciferase enzymatic 
activity. The interaction between luciferin and luciferase generates visible light which 
can be detected through imaging devices and expressed as rate of genetic/plasmidic 
activity. This technology has many attractive applications. It is possible for example to 
quench the bioluminescence activity of luciferase expressing tumor cells while treating 
them with siRNA specific for this coding sequence. If we deliver mRNA-specific siRNA 
into the target cell, the translation of the luciferase gene is blocked and knock-down in 
photon emission is registered after administration of luciferin. 
 
 
 
 
 
 
Doctoral Thesis by Massimo Concia                                                                                                      Introduction 
6 
 
1.5 Fluorescence and its in vivo applications 
 
1.5.1 Fluorescence and fluorescent dyes 
 
Fluorescence is an optical phenomenon where absorption of a photon by a molecule 
causes the emission of another photon with longer wavelength. The energy gap 
between absorbed and emitted photons ends up as molecular vibrations or heat. 
Fluorescence occurs when molecules or nanostructures relax to their ground state 
after being electrically excited. 
Plenty of biological molecules have strong fluorescent properties due to specific 
chemical groups (fluorophores) that can be utilized in many different ways. Automated 
DNA sequencing by chain termination method, DNA detection with ethidium bromide 
and DNA microarrays for instance are important molecular biology techniques that use 
fluorescent phenomena. Also in Pathology and Immunology important assays have 
been developed like fluorescence microscopy of tissues and immunofluorescent tests, 
commonly used in diagnostics. Concerning cell culture technologies Fluorescent-
Activated Cell Sorting (FACS) has become a routine investigation method. 
In vivo imaging represents a major application of fluorescence for gene therapy. It 
resembles fluorescence microscopy in that both utilize a low-light camera and collect 
emission signals through adequate filter combinations. Its object is an animal organism 
administered with fluorescent labeled molecules and vectors. The aim of this sector is 
to check and quantify the fluorescence signal intensity coming from the body giving 
optical data about total-body and organ-specific diffusion, excretion and toxicity. Body 
imaging presents distinctive features due to the peculiar fluorescence absorption and 
emission patterns of different organs and tissues. This organism-specific fluorescence 
is called auto-fluorescence and implies that all molecules to be administered have 
different spectral properties from body tissues and fluids in order to avoid signal loss 
by overlapping. Other properties of this molecules class are biological stability, 
preferential accumulation at an intended target site or organ and low toxicity[30]. 
 
The green fluorescent protein (GFP) is made up of 238 amino acids and absorbs light 
between 380 and 488 nm. A cDNA of GFP was first obtained by Prasher in 1992[31]. 
Afterwards GFP was used as marker for other proteins and became a standard in 
molecular biology. GFP has great importance in cellular and molecular biology but its 
applications in vivo imaging are limited because its emission wavelength coincides with 
some blood pigments such as hemoglobin[32]. 
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Cy3 and Cy5 of the dye family of cyanines can be coupled with different reactive 
groups with affinity to either nucleic acids or proteins. Cy3 is excited at 550 nm and 
emits at 570 nm in the red part of the spectrum; Cy5 is excited at 649 nm and emits at 
670 nm in the far red part of the spectrum. Both dyes are used in a wide variety of 
molecular biological applications including comparative genomic hybridization and 
gene chips. They are also utilized to label proteins for various purposes including 
proteomics. Owing to their relative distance from the emission patterns of the animal 
body fluids, Cy3 and Cy5 have some applications in vivo study. However they are not 
optimal for imaging of rodents due to the strong overlapping spectrum with 
chlorophyll (emission peaks between 600 and 700 nm) which constitutes the basis of 
the feeding of these animals. On the contrary near infrared (NIR) dyes are adapted for 
in vivo imaging of rodents because their emission wavelengths (larger than 700 nm) 
are located in a biological windows free from overlapping phenomena. 
 
1.5.2 Indocyanine green (ICG) 
 
Indocyanine green (ICG) is a tricarbocyanine dye used intravenously as diagnostic aid 
for determination of blood volume, cardiac output and hepatic function.  
ICG absorption and emission spectra are in the near infrared spectrum (excitation and 
emission have their maximum at 765 and 830 nm in water). ICG is able to bind to 
plasma proteins remaining in the blood vessels for long time. It is excreted through the 
biliary tract and not reabsorbed in the intestine; furthermore it has low-toxicity. 
Considering its effective binding to plasma proteins ICG is considered a perfusion 
marker of organs like liver and spleen. Plasmatic ICG concentration after intravenous 
administration well correlates with liver function. Other important applications of this 
fluorescent dye are myocardial perfusion studies[33], oncological staging[34][35] and eye 
diagnostics (e.g. ICG angiography)[36][37]. 
Indocyanine green has very attractive biological properties and its near infrared 
spectral characteristics are not disturbed by the fluorescence emission of other 
molecules contained in the animal body compartments. Unfortunately ICG derivatives 
with amino-reactive groups for binding to PEI are not commercially available at the 
moment. 
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1.5.3 Quantum Dots 
 
A quantum dot (QD) is a nanometer-sized (ranging from >1.5 to <8 nm) crystalline 
structure, made up of semiconductors. The electrons movements in a quantum dot are 
strictly confined in the three dimensions so that their energy cannot vary in a 
continuous way but only at discrete steps.  
Quantum dots usually consist of the semiconductor core (e.g.: Cd-Se, In-Ga-As, or Ga-
In-P/In-P) and the shell containing reactive groups that modify the optical and chemical 
properties of these nanocrystals permitting binding to different biomolecules. 
Quantum dots are gaining interest as fluorescent tags for biological molecules thanks 
to their stronger fluorescence and better photo-stability than organic fluorescent dyes. 
They also exhibit broader absorption and narrower emission ranges than most 
fluorescent dyes[38][39][40][41][42]. 
While the material, which makes up a quantum dot, determines its intrinsic energy, its 
emission wavelength is defined by its size. For this reason quantum dots with identical 
chemical structure but different dimensions emit light of different colors. The 
wavelength and color of the emitted light is directly proportional to the size of a 
quantum dot. Like wavelength (i.e. color) of emitted light fluorescence lifetime of a 
quantum dot is a function of size in that large quantum dots contain more energy 
levels than “little” ones. These energy levels are also more spaced in large dots and it is 
more probable that an electron pair is trapped within the crystal for longer time. 
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1.6 Aim of the Study 
 
The application of gene therapy technologies needs controlling systems to be able to 
state how efficient the delivery process is. At the Chair of Pharmaceutical 
Biotechnology, Department, of Pharmacy, Ludwig-Maximilians-Universität München 
(LMU) non-viral gene delivery systems are developed, whose efficiency is tested with 
methods based on bioluminescence and fluorescence in vitro and in vivo[43][44]. 
Fluorescence-labeled gene carriers can be efficiently detected in vivo, if the 
fluorescent markers emit in a different spectral area from other substances (such as 
hemoglobin, chlorophyll, etc.), whose strong radiation would cover the lower dye 
emission intensity. In order to avoid such overlapping phenomena fluorescent, dyes 
emitting in the near infrared region (NIR) are required. These dyes for in vivo purposes 
should be not toxic and can be administered intravenously.  
 
The aim of this study was to determine what dyes were suitable for our in vivo 
imaging system, whose emission could be detected and quantitatively analyzed. We 
wanted to assess what conjugates based on polyethylenimines (PEI) or 
oligoethylenimines (OEI) were at most adapted for our experiments in vivo using 
fluorescent dyes. Could EGF and transferrin positively impact the gene delivery in 
selected tumor cell lines expressing their specific receptors? Was it possible to 
further improve our results using PEG-shielding? We finally wanted to determine if it 
is possible to quantitatively measure the accumulation of fluorescence labeled gene 
carriers in the tumor tissue. 
 
In this study commercially available organic dyes and quantum dots (synthesized by 
the work group of Dr. Andrey Rogach, LMU) were used with emission spectra between 
750 and 800 nm. We tested fluorescence labeled PEI-based gene vectors in 
immunodeficient mice bearing subcutaneously implanted human or murine tumors 
cell lines (HUH7, N2a). The gene carriers were additionally coupled to ligands (EGF, 
transferrin) whose receptors are strongly expressed on the surface of the implanted 
tumor cells. 
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2 Materials and methods 
 
2.1 Chemicals and reagents 
 
Branched PEI (brPEI) with an average molecular weight (Mw) of 25 kDa was purchased 
from Sigma-Aldrich™ (München, Germany). HD O (Mw 4000 Da; OEI 800 Da core 
modified with hexane-1,6-diol diacrylate and surface-modified with OEI 800 Da) was 
synthesized by Dr Verena Ruß, as described in literature[22]. Murine recombinant EGF 
(mEGF) was obtained from Pepro Tech EC Ltd. (London, United Kingdom). Human 
transferrin (hTf) with iron was supplied by Biotest (Dreieich, Germany). Endotoxin-free 
pCMVLuc plasmid (Photinus pyralis luciferase under control of the CMV 
enhancer/promoter) was produced by Plasmid Factory GmbH & Co (Bielefeld, 
Germany). Alexa Fluor® 750 carboxylic acid, succinimidyl ester was purchased from 
Invitrogen Corporation (Carlsbad, California, USA), NIR 797 isothiocyanate from Sigma-
Aldrich Reagents (Munich, Germany). The quantum dots stock-solutions (Cd-Te core 
with S-C3H6-COO- groups) are produced by Dr Andrei Susha at the Faculty of Physics, 
Photonics and Optoelectronics Group, LMU, led by Dr Andrey Rogach (emission 650-
870 nm, peak emission 790 nm; size: 7 nm). Saline Solution (0.9 %) for intravenous 
injections was provided by B.Braun Melsungen AG (Melsungen, Germany). 
Dimethylsulfoxide (DMSO) was obtained from Fluka Chemie GmbH (Deisenhofen, 
Germany). All other regents were purchased from Sigma-Aldrich (Munich, Germany).  
 
 
2.2 Synthesis of conjugates and polyplexes 
 
2.2.1. Synthesis of conjugates 
 
All conjugates were synthesized at the Chair of Pharmaceutical Biotechnology (LMU) 
by Wolfgang Rödl, Dr Arkadi Zintchenko and Dr Verena Ruß. PEG20-brPEI25 (with 
molar ratio PEG/PEI=2:1) and hTf-PEG3.4-brPEI25 conjugates linked with a hetero-
bifunctional 3.4 Da PEG derivative were synthesized and purified as previously 
described[45]. hTf-brPEI25 conjugate (molar ratio Tf/PEI 1/1 M/M) was synthesized as 
described by Kircheis et al[46]. mEGF-PEG3,4-brPEI25 (murine EGF conjugated to 
branched PEI 25 kDa via a 3,400 Da PEG-spacer) was synthesized as described by 
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Wolschek et al
[47]; mEGF-brPEI25 conjugate has been produced as described by 
Blessing et al
[48]. 
 
Alexa 750/brPEI25 conjugate was synthesized as follows: 256 nmol PEIbr25 were 
dissolved in 1 ml HEPES-buffered saline (HBS) at 10 mg/ml (pH=7.4). While vortexing 
the PEI solution 768 nmol Alexa Fluor® 750 carboxylic acid, succinimidyl ester (Mw 
1300; ex/em=746/775 nm) were slowly added: molar ratio Alexa 750/PEIbr25 = 3:1. 
The reaction was incubated 2 hours at room temperature (RT) with continuous stirring. 
The conjugate was separated from unreacted labeling reagents using Sephadex G25, 
BioGel gel filtration (HR 10/30, HBS, 1:1 with H2O; 0.5 ml/min). Branched PEI 
concentration was determined by trinitrobenzesulphonic acid (TNBS) assay; Alexa 750 
concentration calculated from the absorption at 700 nm (molar extinction coefficient 
Alexa ε= 240,000/mol*cm). The final molar ratio Alexa/PEI was 1/1 M/M. 
 
Alexa 750/H DO conjugate was obtained following the same protocol, mixing Alexa 750 
dye and H DO with a molar ratio dye/polycation = 3:1 Two different fractions of Alexa 
750/HD O conjugate were obtained differing in their Alexa 750 concentration: #1 45 
µM, #2 12 µM Alexa. Fraction 1 showed a final degree of Alexa 750 labeling of 1/2.4 
(Alexa 750-HD O, M/M) and fraction 2 of 1/5.6 (Alexa 750-HD O, M/M). 
 
NIR 797-brPEI25 conjugates were synthesized as follows:  
Conjugate A: 
80 µl of NIR 797 [1,1'-Bis(4-sulfobutyl)-11-(4-isothiocyanatophenylthio)-3,3,3',3'-
tetramethyl-10,12-trimethylenindotricarbocyanine monosodium salt, Molecular 
Formula: C45H50N3NaO6S4, Mw 880.14, fluorescence: λex 795 nm; λem 817 nm in 0.1 M 
phosphate pH 7.0] in dimethyl sulfoxide (DMSO, 25 mg/ml) were added to 1 ml of the 
brPEI25 solution (10 mg/ml) in 0.1 M carbonate buffer (pH=9). The reaction mixture 
was incubated for four hours at 37˚C. Labeled polymers were separated from 
unreacted dye by size exclusion chromatography (Sephadex G25 HR 10/30, 20 mM 
HEPES, pH=7.4, 0.15 M NaCl) and desalted by ultrafiltration. Branched PEI 
concentration was determined by TNBS assay for primary amino groups; NIR 797 
concentration was calculated from the absorption at 700 nm (molar extinction 
coefficient NIR: ε = 48500/mol*cm). The final degree of NIR labeling NIR/PEI = 0.98/1. 
Conjugate B: 
400 µl of NIR 797 [1,1'-Bis(4-sulfobutyl)-11-(4-isothiocyanatophenylthio)-3,3,3',3'-
tetramethyl-10,12-trimethylen-eindotricarbocyanine monosodium salt, Molecular 
Formula: C45H50N3NaO6S4, Mw 880.14, fluorescence: λex 795 nm; λem 817 nm in 0.1 M 
phosphate pH 7.0] in dimethyl sulfoxide (DMSO, 25 mg/ml) were added to 1 ml of the 
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branched PEI25 solution (10 mg/ml) in 0.1 M carbonate buffer (pH=9). The reaction 
mixture was incubated for four hours at 37˚C. Labeled polymers were separated from 
unreacted dye by size exclusion chromatography (Sephadex G25 HR 10/30, 20 mM 
HEPES, pH=7.4, 0.15 M NaCl) and desalted by ultrafiltration. Branched PEI 
concentration was determined by TNBS assay for primary amino groups; NIR 797 
concentration was calculated from the absorption at 700 nm (molar extinction 
coefficient NIR ε = 48500/mol*cm). The final degree of NIR labeling NIR/PEI = 6/1. 
 
2.2.2. Generation of polyplexes 
 
Polyplexes were generated with a final DNA concentration of 200 µg/ml at an N/P ratio 
(molar ratio nitrogen in PEI to phosphate in pDNA) of 6 in HBG (HEPES buffered 
glucose; 20 mM HEPES pH 7.1, 5% glucose w/v) as described in literature[49][50], and 
rapidly mixed by pipetting. Polyplexes were allowed to stand for at least 20 min at 
room temperature before use. Previous studies[51][52] revealed that generating PEI-
based polyplexes at an N/P ratio of 6 is most favorable for in vivo, resulting in efficient 
transfection and minimized toxicity[53]. 
 
N/P ratio 6 was calculated as follows: for each P in DNA an average molecular weight 
of 330 Da was calculated; the average molecular weight of one N-containing repeating 
unit in PEI (-CH2-CH2-NH) was calculated as 43 Da. For a known concentration of DNA 
corresponding PEI concentration was calculated as follows: [PEI] = [DNA]*43*6/330 
 
Standard pDNA-PEI polyplexes were generated in HBG at a final DNA concentration 
200 µg/ml as follows: pDNA was diluted in a reaction tube to 400µg/ml in HBG. In a 
separate vial PEI solution was diluted in the same volume to a final concentration of 
313 µg/ml. Thereafter PEI solution was pipetted to the DNA solution and immediately 
pipetted up/down several times to obtain optimal mixing of both components. 
To obtain pDNA-PEI polyplexes with fluorescently labeled PEI, PEI was replaced by 
Alexa 750/brPEI25 and NIR 797/brPEI25 conjugates (see 2.2.1). 
 
Quantum dots were delivered as stock dispersions 1.2*10-6 M. The standard 
application dose was defined optically through fluorescence emission testing of 
dilution series of the stock solution and put at 2.01 µl stock solution/100 µl injection 
volume. 
 
QD/pDNA-PEI polyplexes were generated as follows: pDNA was diluted in a reaction 
tube to 800µg/ml in HBG. In a separate vial QD suspension was diluted to the final 
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concentration of 7.5*10-4 nmol/ml. The QD suspension was then added to the DNA 
solution and mixed together quickly. PEI solution was diluted in the same volume as 
DNA-QD mix and subsequently pipetted to the first solution and quickly pipetted 
up/down to obtain small particles. 
QD/PEI conjugates were generated as follows: QD suspension was diluted in a vial to 
3.75*10-4 nmol/ml. In a separate vial PEI solution was diluted in the same volume to a 
final concentration of 313 µg/ml. Thereafter the PEI solution was pipetted to the QD 
suspension and immediately pipetted up/down several times to obtain an optimal 
mixing and small particles. 
 
 
2.3 Analysis of transfection complexes 
 
2.3.1 Measurement of the particle size 
 
Particle size and zeta potential of transfection complexes were measured by laser-light 
scattering using Malvern Zetasizer 3000 HS (by Malvern Instruments, Worchestershire, 
United Kingdom). Polyplexes generated in HBG at 20 μg/ml DNA concentration were 
allowed to stand 30 min prior to measurement. 
 
2.3.2 Electrophoresis 
 
1% agarose gels were prepared by dissolving 1.2 g agarose (by Invitrogen Corporation, 
Carlsbad, California, USA) in 120 ml tris-borate EDTA (TBE) buffer (by Sigma-Aldrich 
Reagents™; Munich, Germany) and boiling the solution up to 100°C. After cooling 
down to 70°C the gel was poured into the electrophoresis unit Sub-Cell GT Cell (by Bio-
Rad Laboratories, Hercules, California, USA). 19 µl of solution to be analyzed were 
mixed with 3 µl of xylene cyanol loading buffer solution from PEQLAB Biotechnologie 
GMBH (Erlangen, Germany), inserted into the gel wells and separated under electric 
field (120 mV, 2 A) for 120 minutes. Electrophoresis gels were then scanned with 
Odyssey® Infrared Imaging System (by LI-COR Corporate Offices, Lincoln, Nebraska, 
USA) to detect near infrared fluorescence after excitation with 700 and 800 nm laser. 
The resulting images were edited with Odyssey® software version 3.0 (by LI-COR 
Corporate Offices). After being scanned for fluorescence the gel was stained in a TBE 
buffer solution containing ethidium bromide (500 ng/ml TBE) for 30 min, and then 
illuminated with an ultraviolet lamp to view the DNA bands. Photographs were taken 
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with an UV-imaging device by Raytest GmbH (Straubenhardt, Germany), and edited 
using AIDA Image Analyzer Software Version 3.21 (Raytest GmbH). 
 
 
2.4  Cell culture 
 
Cell culture media and fetal calf serum (FCS) were purchased from Invitrogen GmbH 
(Karlsruhe, Germany). All cultured cells were grown at 37°C in 5% CO2 humidified 
atmosphere. Human Hepatocellular Carcinoma HUH7 cells (JCRB 0403; Tokyo, Japan) 
were cultured in DMEM/HAM's F12 medium (1:1) supplemented with 10% heat-
inactivated FCS and L-alanyl-L-glutamine 1.6 mmol/500 ml medium (Biochrom, Berlin, 
Germany). Murine neuroblastoma N2a cells (ATCC CCl-131) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS with 10% heat-
inactivated FCS and L-alanyl-L-glutamine 1.6 mmol/500 ml medium at 37°C in 5% CO2 
humidified atmosphere. 
Doctoral Thesis by Massimo Concia                                                                                  Materials and methods 
 
15 
 
Animal experiment
*
 
 
2.5.1 Animal husbandry 
 
4 weeks old female nu/nu mice were delivered by Elevage Janvier (Le Genest-Saint-
Isle, France). The animals were housed under pathogen-free conditions in individually 
ventilated cages (type 2L by Techniplast IVC Sytems, Buguggiate, Italy), 5 mice/cage 
under controlled light (12 hours light/12 hours darkness), temperature (21–22°C), 
humidity (60%). They were fed with autoclaved chlorophyll-free experimental mouse 
chow (product code: E_15000-04 by Ssniff Spezialdiäten, Soest, Germany) and fresh 
water ad libitum. Each cage was fitted with wood shavings made from debarked aspen 
wood (by ABEDD® LAB & VET Service GmbH, Vienna, Austria), equipped with a wooden 
rodent tunnel (size 2; ABEDD® LAB & VET Service GmbH, Vienna, Austria) and a red 
transparent plastic lodge (by Techniplast IVC Sytems, Buguggiate, Italy). After being 
delivered all animals were habituated for a week to the new environment conditions 
before starting any treatment. 
 
2.5.2 Tumor cells implantation 
 
As described in 2.4 the tumor cells (HUH7 or N2a) were harvested after reaching 70-
80% confluence. Cell culture medium was removed and the tumor cells were washed 
twice with phosphate-buffered saline (PBS). They were then incubated with 
trypsin/EDTA for 5 minutes at 37˚C and separated from their support. After 
inactivating trypsin solution with culture medium containing fetal bovine serum (FBS) 
the cells were suspended with fresh medium and centrifuged (5 min, 1300 rpm, 4˚C). 
The supernatant was then discarded and the cells resuspended in PBS and centrifuged 
again at the same conditions. After this second centrifugation 1µL of cells suspension 
was taken and put into a Rosenberg’s counting chamber to be counted. According to 
the tumor type 1x106 N2a cells/mouse and 5x106 HUH7 cells/mouse were collected 
and suspended in 100 µL PBS at 4˚C. The cell suspension was injected with a 25 G 
needle (by B.Braun Melsungen AG, Melsungen, Germany) into the left/right or bilateral 
loin region. 
                                                 
*
All experimental procedures with living animals in our laboratories were approved by the Upper Bavarian 
Government (Regierung Oberbayern) complying with the Guidelines of the Council of Europe (24.9.86) and the 
German Animal Protection Law (Tierschutzgesetz, 18.5.05). 
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2.5.3 Tumor volume measurements 
 
The sizes of the implanted tumors were measured every other day with a digital caliper 
(by HELIOS-PREISSER Vertriebszentrum, Gammertingen, Germany). Tumor’s ength, 
width and height were registered. About 0.3 cm3 of tumor volume was considered 
optimal for starting in vivo assays. 
 
2.5.4 Intravenous applications and anesthesia 
 
Mice were immobilized in a restrainer and their tail submersed in water warmed to 
40˚C for 2 minutes to dilate the superficial tail veins. The solution (12.5 µL/g mouse) 
was injected intravenously using an U-40 sterile insulin syringe with a 29 G needle 
(Beckton Dickinson, Franklin Lakes, NJ, USA) and the animal put into the anesthesia 
chamber of IVIS® Lumina imaging system 100 Series (by Xenogen Corp, Alameda, 
California, USA). Anesthesia was induced with 2% isoflurane gas (cp-pharma 
Handelsgesellschaft mbH, Burgdorf, Germany) in oxygen. 
 
For standard-dose applications pDNA-PEI and QD/pDNA-PEI polyplexes were injected 
at 2.5 mg/kg DNA dose (corresponds to PEI dose of 1.95 mg/kg) and QD/PEI polyplexes 
at final PEI dose of 1.95 mg/kg. In certain experiments fluorescently labeled PEI alone 
was injected. Labeled PEI was diluted to a final concentration of 0.156 µg/ml in HBG 
and injected intravenously at a PEI dose of 1.95mg/kg (standard dose) or 1.3 mg/kg 
(reduced dose). QD alone were applied at a dose of 0.75 nmol/kg (105 particles/l). 
 
2.5.5 Dissection and organs excision 
 
Fluorescent emission images of anesthetized mice were taken at different points in 
times after intravenous injection of fluorescent labeled polycations and polyplexes. All 
animals were then euthanized by inhalation of CO2. Afterwards they were fixed onto a 
plastic support with pins and dissected; their organs were excised and put on a Petri 
dish. Fluorescence emission images of dead animals were taken after opening their 
abdominal cavity and exposure of their organs. 
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2.6 In vivo imaging procedures 
 
2.6.1 In vivo imaging system: imaging adjustments 
 
The anesthetized animals were placed into the IVIS® Lumina imaging system 100 Series 
(by Xenogen Corp, Alameda, California, USA). During the imaging process the mice 
were kept under anesthesia by 2% isoflurane gas in oxygen. Most images were 
obtained using the ICG/ICG (excitation/emission: 710-760/810-875) filter combination 
(mode: fluorescence; exposure time: 1 sec; binning: high; block filter: on; tray position: 
A/D). 
 
Physical Units for fluorescence Imaging:  
 
Photons/sec: imaging data are displayed in terms of absolute photon emission from 
the source (a 150-W quartz-tungsten halogen lamp). 
 
Efficiency: non uniformity in the illumination profile is corrected for by dividing images 
by a stored reference image (normalization). 
 
2.6.2 Measurements and data analysis 
 
Fluorescence imaging data were edited in photons/sec using Living Image 260.1-IGOR 
Pro 4.09 Software (by Xenogen Corp, Alameda, California, USA). All signal emission 
values were inserted into a file sheet using Microsoft® Excel 2006 (by Microsoft® 
Corporation, Redmond, Washington, USA).  
 
2.6.3 Statistical analysis 
 
For statistical analysis of imaging data paired and unpaired t-tests and one-way 
analysis of variance (ANOVA) were performed using Prism 5 for Windows (by GraphPad 
Software, Inc., San Diego, CA, USA) and WinStat for Microsoft® Excel 2006. 
A p value < 0.05 was considered to be significant.
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3 Results 
 
 
3.1 Near infrared fluorescent dyes: biodistribution of dyes, conjugates 
with polycations and pDNA-polyplexes 
 
3.1.1 Alexa 750 and NIR 797: biodistribution of free dyes 
 
3.1.1.1 Alexa 750 free 
 
This was a preliminary experiment to evaluate the usability of Alexa 750 for in vivo 
imaging with the IVIS system, describing distribution patterns of free Alexa 750, its 
fluorescent signal intensity, its emission decay and toxicity after iv application in living 
animals. 
 
 
Animals: 5 nu/nu mice, male; 5 weeks old; tumor free. 
 
 
Considering previous literature experience[29] we administered 5 nmol/animal of Alexa 
750 dissolved in HBG (HEPES buffered glucose) solution (12.5 µl/g mouse) into the 
animals’ tail vein. 
 
Application scheme: 
 
Mice 1,2,3,4   5 nmol Alexa 750 in HBG 
      
Mouse 5 (ctrl)   HBG buffer 
  
   
Body fluorescence emission signals were checked 15 minutes and 24 hours after 
systemic injection. All animals were then sacrificed and their organs were excised, 
checked for fluorescence emission and then frosted in order to be analyzed separately. 
We tried to detect fluorescence in organ homogenates but we could not register any 
signal. 
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Fig. 1a,b: 2 animals treated with 5 nmol Alexa 750 alone (left) and the control mouse 15 
minutes and 24 hours after iv application (filter ex/em: ICG/ICG).  
Regions of interest marked with red circles (n=4; ctrl=1). 
 
a: ventral signal after 15 minutes 
 
b: ventral signal after 24 hours 
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Fig. 3: fluorescence emission signal in photons/sec from thorax/neck (thyroid) 15 minutes and 
24 hours after iv application of 5 nmol Alexa 750 free (n=4; ctrl=1). 
 
 
 
 
Fig 4: fluorescence emission signal in photons/sec from pelvis/bladder 15 minutes and 24 hours 
after iv application of 5 nmol Alexa 750 free (n=4; ctrl=1). 
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Fig. 5a,b: excised organs of mouse treated with 5 nmol Alexa 750 free and the control mouse 
24 hours after iv application (filter ex/em: ICG/ICG; n=4; ctrl=1). 
T=thyroid; RL, LL=right, left lung; H=heart; Li=liver; Sp=spleen; RK, LK=right, left kidney. 
 
a: Alexa 750 free 
 
 
b: control 
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At both time points (15 min, 24 hrs) after injection of 5 nmol Alexa 750 bladder, 
thyroid and lungs showed the most intense signals (fig. 4a-b). Ex vivo imaging data 
visualized strong thyroid dye accumulation after organ excision (fig. 5a-b). All 
fluorescence signal values decreased in similar way after 24 hrs (fig. 3 and 4). No 
acute/subacute toxic effects were observed because free Alexa 750 did not cause 
aggregation of red cells in the blood stream. 
 
 
3.1.1.2 NIR 797 free 
 
We repeated the same experiment with NIR 797 (same dosage: 5 nmol/animal) to 
compare its properties with Alexa 750. The goal was evaluating the usability of NIR 797 
for in vivo imaging with the IVIS system, describing distribution patterns of free NIR 
797, its fluorescent signal intensity, its emission decay and toxicity after iv application 
in living animals.  
 
 
Animals: 3 nu/nu mice, female; 8 weeks old; bearing HUH7 cells tumors. 
 
 
We administered 5 nmol/animal of NIR 797 dissolved in HBG buffering solution (12.5 
µl/g mouse) into the animals’ tail vein. 
 
Application scheme: 
 
Mice 1,2   5 nmol NIR 797 in HBG 
      
Mouse 3 (ctrl)   HBG buffer 
 
 
Body fluorescence emission signals were checked 15 minutes, 6, 24 and 48 hours after 
the systemic injection. 
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Fig. 1a,b: ventral and left-side images of 2 animals treated with 5 nmol NIR 797 alone (left) and 
the control mouse 15 minutes after iv application (n=2, ctrl=1; filter ex/em: ICG/ICG).  
Regions of interest marked with red circles. 
 
a: ventral (liver)signal after 15 minutes 
 
 
b: left side (tumor) signal after 15 minutes 
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Fig. 2: ventral (liver) fluorescence emission signals in photons/sec 15 minutes, 6, 24 and 48 
hours after iv application of 5 nmol NIR 797 free (n=2; ctrl=1). 
 
 
 
 
Fig 3: dorsal fluorescence emission signals in photons/sec 15 minutes, 6, 24 and 48 hours after 
iv application of 5 nmol NIR 797 free (n=2; ctrl=1). 
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Fig. 4: left side (tumor) fluorescence emission signals in photons/sec 15 minutes, 6, 24 and 48 
hours after iv application of 5 nmol NIR 797 free (n=2; ctrl=1). 
 
 
 
 
 
Unlike Alexa 750 NIR 797 tended to accumulate within the liver in presence of scarce 
thyroid and moderate lungs depots (fig. 1a-b). NIR 797 had slightly lower emission 
signals compared to Alexa 750 at any time point and observation area. All fluorescence 
values decreased in a similar way while control mouse emission values did not change 
(fig. 2, 3 and 4). Low fluorescent signals could be checked within the tumor tissue (fig. 
1b and 4). No acute/subacute toxic effects were observed, thus confirming the 
absence of cells aggregation in presence of free dyes. We stated a distinctive tropism 
for hepatic tissue of non conjugated NIR 797. Considering the results obtained by 
application of free Alexa 750 and NIR 797, we planned following experiments with PEI-
conjugated Alexa 750 and NIR 797 in order to check modifications of their 
pharmacokinetic properties and toxicity. 
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3.1.2 Alexa 750/PEI
*
 and Alexa 750/HD O: biodistribution in tumor bearing animals 
 
After the distribution of free fluorescent dyes (Alexa 750 and NIR 797) the next step 
was describing the distribution patterns of Alexa 750/PEI and Alexa 750/HD O 
conjugates, their fluorescent signal intensities, emission decay and toxicity. We aimed 
at checking any modification in distribution and particularly verifying if the 
predominant accumulation in thyroid/lungs and bladder for Alexa 750 and liver for 
NIR797 persists and toxicity occurs after dye/PEI (or OEI) complexing. 
 
 
Animals: 7 nu/nu mice, female; 6 weeks old; bearing HUH7 cells tumors. 
 
 
Respecting the standard applications dose for PEI/OEI (in presence of 200 µg/ml DNA 
or RNA: N/P ratio=6) we injected 0,378 nmol Alexa 750 conjugated to PEI into each 
animal. Two different Alexa 750-HD O conjugates were applied differing in their dye 
molarity: conjugate 1 (#1): 45 μM Alexa 750, dye/HD O=1/2.4 M/M; conjugate 2 (#2): 
12 μM Alexa 750, dye/HD O=1 /5.6 M/M). 
 
Application scheme: 
 
Mice A1, A4  Alexa750/PEI 
 
Mice B1, B2  Alexa750-/HD O #1 
 
Mice B3, B4  Alexa750-/HD O #2 
 
Mouse A2  ctrl (HBG buffering solution) 
 
    
 
Body fluorescence emission signals were measured 15 minutes, 24 and 48 hours after 
the systemic injection. 
                                                 
*In this and the following chapters branched PEI 25 25kDa is simply indicated as PEI. mEGF and hTf are indicated as 
EGF and Tf. 
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Fig. 1: mouse treated with Alexa 750/HD O (0.378 nmol, left) vs the control animal (right). 
Fluorescence signal is not present in the tumor area. 
(n: Alexa 750/PEI=2, Alexa 750/HD O #1=2, Alexa 750/HD O #2=2, ctrl=1) 
 
 
 
 
Fig 2a,b,c: fluorescence emission signal in photons/sec from a)liver, b)bladder, c)kidneys  
15 minutes, 24 and 48 hours after application of 0,378 nmol Alexa 750/PEI and Alexa 750/HD O 
(n: Alexa 750/PEI=2, Alexa 750/HD O=2 #1, Alexa 750/HD O=2, ctrl=1) 
 
a: liver signal 
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b: bladder signal 
 
 
 
c: renal signal 
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All fluorescence signals decreased in a similar way after 24 hours while emission values 
did not significantly change in the control mouse (fig. 2a,b,c). Bladder and kidneys 
signal at early time points (15 min) were stronger than the liver’s but decayed faster. 
This was likely due to the high rate of conjugates elimination through the kidneys 
filtration during the first hours after systemic application. No signals were observed in 
the tumor (fig. 1). The thyroid/lungs accumulation 15 minutes after administration, 
detected using free Alexa 750, was not observed anymore. The increased particles size 
had modified the kinetic properties of the free dye. Unlike PEI-based conjugates 
Alexa/HD O spread through joints and connective tissue due to its inferior size. These 
data demonstrated that stronger dye labeling for our PEIs or OEIs was necessarily to 
detect emission intensities comparable to those of Alexa 750 free. Our group had 
much more experience with PEI-based conjugates in vitro and in vivo than with OEI so 
we decided to continue our tests using just PEI. 
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3.1.3 NIR797/PEI: influence of dye/PEI ratio on biodistribution and imaging 
properties 
 
After the distribution of free fluorescence dyes (Alexa 750 and NIR 797) and of Alexa 
750/PEI and HD O conjugates the next step was describing the distribution in vivo of 
NIR 797/PEI conjugates. 
 
3.1.3.1 NIR 797/PEI conjugates (I) 
 
This firs assay with NIR 797/PEI conjugates describes spreading and accumulation 
patterns of NIR/PEI conjugates at different dye/PEI labeling ratios with or without 
nucleic acid, their fluorescent signal intensity, emission decay and toxicity after iv 
application in living animals. Our intention was to check any modification in 
distribution and particularly verify if predominant accumulation in liver persists. We 
wanted also to observe if toxicity phenomena occur after dye/PEI conjugation. 
 
 
Animals: 3 nu/nu mice, female; 8 weeks old; tumor free. 
 
 
We tested two differently labeled NIR 797/PEI conjugates synthesized in our 
laboratory: 
 
conjugate A:  dye/PEI ratio = 0.98:1  
 
conjugate B:  dye/PEI ratio = 6:1 
 
 
Conjugate B showed a much stronger labeling. Better fluorescent signal were to be 
expected. 
 
 
Application schema: 
 
Mouse 1  unlabeled PEI (control)  
 
Mouse 2  NIR797/PEI conjugate A 
 
Mouse 3  NIR797/PEI conjugate B  
 
 
Body fluorescence emission signals were measured 20 minutes, 20, 48 and 72 hours 
after the systemic injection. 
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Fig. 1: fluorescence emission signal in photons/sec from abdomen (liver) 15 minutes, 20, 48  
and 72 hours after iv application of two differently labeled NIR/PEI formulations: conjugate A, 
(dye/PEI ratio=0.98:1, mouse 2) vs conjugate B (dye/PEI ratio=6:1, mouse 3) vs control 
(unlabeled PEI, mouse 1). 
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Conjugate B (dye/PEI ratio=6:1; mouse 3 in fig. 1) had better imaging properties than B 
(dye/PEI ratio=0.98:1; mouse 2 in fig. 1) owing to stronger labeling, as expected. 
Mouse 1 (control), administered with unlabeled PEI, displayed the lowest signal 
intensity. Fluorescence signal emission was detected mostly in the liver, as observed 
using non-conjugated NIR 797. In this case the dye distribution pattern was not 
modified by conjugation with PEI unlike using Alexa 750. In this and in following assay 
the signal intensity was lower than using free NIR 797, because of the lower amount  
(< 1 nmol) of injected NIR 797 as requested by conjugating with PEI. 
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3.1.3.2 NIR 797/PEI conjugates (II) 
 
This second assay on NIR 797/PEI conjugates describes the distribution patterns of NIR 
797/PEI conjugates and NIR 797/PEI-DNA polyplexes, their fluorescent signal intensity, 
emission decay and toxicity after iv application in living animals. 
As in the previous experiment we intended to verify changes in distribution properties 
and toxicity, even those after complexing with DNA. 
 
 
Animals: 5 nu/nu female mice, 12 weeks old; tumor-free 
 
 
The following experiment was performed utilizing conjugate B of previous report 
(dye/PEI ratio = 1:6).  
 
Application scheme:  
 
Mouse 1 pCMV-PEI + HBG 
 
Mouse 2 pCMV-PEI + HBG 
  
Mouse 3 NIR 797/PEI + HBG 
 
Mouse 4  NIR 797/PEI + HBG 
 
Mouse 5  HBG (control) 
 
 
Body fluorescence emission signals were checked 15 minutes, 20, 48 and 72 hours 
after the systemic injection.  
Mice 3 and 4 died 2 hours after iv application. 
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Fig 1a,b: fluorescence emission signal (photons/sec) from abdomen and dorsal region 15 
minutes, 20, 48  and 72 hours after iv application of NIR 797IPEI-DNA polyplexes vs NIR 797/PEI 
conjugates vs HBG (control). 
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NIR 797/PEI-DNA polyplexes and NIR 797/PEI conjugates showed comparable 
fluorescent emission mostly in the liver (fig. 1a). The distribution pattern of these 
conjugates was similar to that of free NIR 797. This represented a major difference 
between this dye and Alexa 750, whose distribution had considerably changed after 
conjugation with PEI and OEI. We attested the acute/subacute toxicity of NIR 797/PEI 
conjugates. The cause of this phenomenon could have been the absence of DNA 
negative charge, which interacted with the positively loaded carrier, avoiding a too 
strong erythrocyte aggregation within the pulmonary circulation during the first hours 
after injection. Animals older than 8 weeks are anyway particularly susceptible to 
adverse effects. 
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3.2 Near infrared emitting quantum dots as novel tools for bioimaging 
of polyplexes 
 
We decided to test quantum dots (QD) because of their strong fluorescence and very 
low production cost in co-operation with the Department of Physics of the LMU. 
 
3.2.1 Fluorescent properties of different quantum dots formulations 
 
The first experiment consisted in testing fluorescence properties of different quantum 
dots (QD) formulations compared to a standard preparation of anionic QD with a Cd-Te 
core and a shell containing S-C3H6-COO- groups.  
 
We also tried to assemble zwitterionic particles endowed with a neutrally charged 
shell containing cystein with similar fluorescence excitation/emission like our standard 
preparation. The advantage of utilizing neutral nanocrystals consists in eliminating 
unspecific interactions with blood and tissue compounds. Unfortunately their 
fluorescence intensity was too weak for in vivo applications (fig. 1 and 2). The signal 
intensity of the anionic (acid) QD standard formulation is 10-fold higher than the 
zwitterionic (neutral) QD.  
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Fig. 1a,b: dilution series of zwitterionic vs anionic quantum dots. QD concentrations are: 
- 1.2, 0.6, 0.3, 0.15, 0.075, 0.0375 mmol/l (left: zwitterionic Cd-Te QD) 
- 0.6, 0.3, 0.15, 0.075, 0.0375, 0.0188, 0.0094, 0.0047 mmol/l (right: anionic Cd-Te QD). 
 
a: zwitterionic QD      b: anionic QD  
 
 
Fig. 2: dilution series of zwitterionic (red bars) vs anionic quantum dots (blue bars). For both 
groups QD concentrations are: 1.2, 0.6, 0.3, 0.15, 0.075, 0.0375 mmol/l corresponding to tubes 
1 to 6. 
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3.2.2 Biodistribution of QD, QD/PEI and QD/pDNA/PEI polyplexes in nu/nu mice 
 
The first experiment with QD was a distribution study and toxicity evaluation of anionic 
QD, conjugated with PEI and PEI-DNA (pCMV) polyplexes. We aimed at checking the 
fluorescent properties of these dyes to compare them with the organic dyes (Alexa 750 
and NIR 797) and verifying signal modifications after complexing of QD with PEI and 
PEI-DNA. 
 
 
Animals: 6 (2 males and 4 females) nu/nu mice, 5 weeks old; tumor-free   
 
 
Application scheme: 
 
Mouse 1  QD + PEI-DNA  
 
Mouse 2 QD + PEI-DNA 
  
Mouse 3  QD + PEI 
 
Mouse 4  QD + PEI 
 
Mouse 5 QD 
 
Mouse 6  HBG buffer (ctrl) 
 
 
Body fluorescence emission was checked 15 minutes and 6 hours after systemic 
injection. Thereafter All animals were sacrificed and their organs excised, in order to 
separately measure their specific fluorescence emission. 
Doctoral Thesis by Massimo Concia                                                                                                               Results 
 
38 
 
 
Fig. 1a,b: in vivo fluorescence emission signal (photons/sec) 20 minutes and 6 hours after iv 
application of free QD (left) vs control (middle); n: QD/PEI-DNA=2, QD/PEI=2, QD free=1, ctrl=1. 
 
   a: after 20 minutes    b: after 6 hours 
 
 
 
 
Fig. 2c,d: in vivo fluorescence emission signal (photons/sec) 20 minutes and 6 hours after iv 
application of QD/DNA-PEI polyplexes (left) vs control (middle) vs QD/PEI (right); n: QD/PEI-
DNA=2, QD/PEI=2, QD free=1, ctrl=1. 
 
  c: after 20 minutes       d: after 6 hours 
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Fig. 3: fluorescence emission signal (ph/sec) 20 minutes and 6 hours after iv application of 
QD/DNA-PEI polyplexes vs QD/PEI vs free QD vs control from the abdominal region (liver). 
n: QD/PEI-DNA=2, QD/PEI=2, QD free=1, ctrl=1. 
 
 
 
 
Fig. 4: ex vivo fluorescence emission signal (ph/sec) of excised organs 6 hours after iv 
application of QD/DNA-PEI polyplexes vs QD/PEI conjugates vs QD alone vs control. 
n: QD/PEI-DNA=2, QD/PEI=2, QD free=1, ctrl=1. 
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Fig. 5a,b,c,d: ex vivo fluorescence emission signal (photons/sec) of excised organs of 4 mice 
after application of QD/PEI conjugates vs QD/DNA-PEI polyplexes vs free QD vs control. 
B=brain; T=thyroid; RL, LL=right, left lung; H=heart; St=stomach; Li=liver; Sp=spleen;  
RK, LK=right, left kidney; n: QD/PEI-DNA=2, QD/PEI=2, QD free=1, ctrl=1. 
 
a: QD/PEI 
 
 
 
b: QD/PEI-DNA 
 
 
 
 
 
 
Doctoral Thesis by Massimo Concia                                                                                                               Results 
 
41 
 
 
c: free QD 
 
 
 
d: control (fluorescence only present in stomach, containing feeding material) 
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Mice administered with QD/PEI displayed the most intense signal: all animals 
belonging to this group showed the highest liver accumulation intensity (fig. 2c,d and 
5a). Fluorescent signal were detected in lungs for the QD/PEI-DNA group (fig. 2c,d, 4 
and 5b), in bones and joints for the QD “free” group (fig. 1a). Negatively charged 
nucleic acid (DNA) within the polyplexes impacted body diffusion patterns of the 
carriers while enhancing lungs accumulation probably because of increased size. Free 
quantum dots accumulated in bone marrow and joints due to their small size (a similar 
result had been observed using small-sized OEI labeled with Alexa 750 in comparison 
to Alexa 750-PEI conjugates). QD fluorescence was slightly less intense than free Alexa 
750 and comparable to free NIR 797 but the concentration of administered QD was 
much lower (0.75 nmol QD vs 5 nmol organic dye). Moreover QD are much cheaper 
and can be produced by a partner laboratory. Therefore we concluded to continue our 
in vivo tests using QD and to utilize them for DNA delivering studies with implanted 
tumors. 
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3.2.3 Tumor targeting properties of QD labeled polyplexes 
 
3.2.3.1 EGF-R targeting in HUH7 Human Hepatocellular Carcinoma (I) 
 
This was the first assay with tumor bearing animals and QD. We chose first Human 
Hepatocellular Carcinoma HUH cells which overexpress receptors for EGF (EGF-R). We 
aimed at targeting it with our fluorescently labeled vectors carrying EGF on their 
surface using PEI, PEI-EGF conjugates and PEI-EGFP Luc(DNA) polyplexes. 
 
 
Animals:  15 female nu/nu mice, 7 weeks old; 4 mice bearing HUH7 Luc cells  
  tumors and 11 mice tumor free (not implanted). 
 
 
Application scheme: 
 
Mice A1, A2, A3 (tumor free)   QD free  
       
 
Mice B2, C1, C2 (tumor free)   QD/PEI 
Mice B1, B3 (tumor bearing)   PEI st. dose  
 
Mice D1, D2, D3 (tumor free)  QD/PEI/EGFP Luc 
      PEI st. dose  
 
Mice E2, E3 (tumor bearing),   QD/PEI-EGF 
Mouse E1 (tumor free)   PEI-EGF: 2/3 of st. dose) 
 
Mouse C3 (ctrl)    not treated 
 
Considering previous experience we used 2/3 of standard PEI dose for QD/PEI-EGF 
complexes to reduce their size avoiding pulmonary embolism. Particles size was 
measured 30 minutes after separate dilution in HBG and careful mixing of the 
reagents. 
 
- QD/PEI   average size: 117 nm 
 
- QD/PEI/EGFP Luc  average size: 204 nm 
 
- QD/PEI-EGF   average size: 186 nm 
 
We considered these values suitable for iv application into living animals. Body 
fluorescence was detected 15 minutes, 6 and 24 hours after systemic injection. After 
24 hours the mice were sacrificed and their organs (lungs, liver, heart, spleen, kidneys 
and tumor) were excised and checked for fluorescence emission.  
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Fig. 1: mouse A1 (free QD, left) 15 minutes after injection vs ctrl (right). Filter ex/em: ICG/ICG. 
Regions of interest (liver, lungs) marked with red circles. 
n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-EGF=3, ctrl=1 
  
 
 
Fig. 2: mice C1 and C2 (QD/PEI) 15 minutes after injection vs ctrl (right). Filter ex/em: ICG/ICG. 
Regions of interest (liver, lungs) marked with red circles. 
n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-EGF=3, ctrl=1 
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Fig. 3: mouse D1 (QD/PEI/EGFP Luc 15 minutes after injection vs ctrl. Filter ex/em: ICG/ICG. 
Regions of interest (liver, lungs) marked with red circles. 
n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-EGF=3, ctrl=1 
 
 
 
 
Fig. 4: mouse E3 (QD/PEI-EGF) 15 minutes after injection vs ctrl. Filter ex/em: ICG/ICG. Regions 
of interest (liver) marked with red circles. 
n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-EGF=3, ctrl=1 
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Fig. 5a,b: in vivo fluorescence emission signal (ph/sec) 15 minutes, 6 and 24 hours after iv 
injection of free QD vs QD/PEI vs QD/PEI-EGFP Luc vs QD/PEI-EGF vs ctrl in lungs and liver. 
n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-EGF=3, ctrl=1. 
 
a: lungs 
 
 
b: liver 
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Fig. 6: excised organs of mouse E2 (QD/PEI-EGF). 
RL, LL=right, left lung; H=heart; Li=liver; Sp=spleen; RK, LK=right, left kidney, Tu=tumor. 
 
 
 
 
Fig. 7: excised organs of mouse E3 (QD/PEI-EGF).  Fluorescent tumor signal (right down).  
Two little tumor masses are presented on the skin region upside. 
RL, LL=right, left lung; H=heart; Li=liver; Sp=spleen; RK, LK=right, left kidney, Tu=tumor. 
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Fig. 8: excised organs of mouse C3 (control). 
T=thyroid; RL, LL=right, left lung; H=heart; Li=liver; Sp=spleen; RK, LK=right, left kidney. 
 
 
 
Fig. 9: ex vivo organ-specific fluorescence signals (ph/sec). Only mice B1, B3 (QD/PEI), E2, and 
E3 (QD/PEI-EGF) had visible tumors. n: QD free =3, QD/PEI =5, QD/PEI-EGF-DNA=3, QD/PEI-
EGF=3, ctrl=1. 
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In all groups the fluorescence in liver was higher than in lungs due to standardized 
particle size. Hepatic intensities in vivo were in general stronger than pulmonary 
fluorescence (fig. 5a,b). Only mice administered with QD/PEI-EGF showed a 
comparable signal for liver and lung ex vivo (fig. 9). For all animals fluorescence 
emission values decreased over time (fig. 5a,b). In Mice E1, E2, E3 (QD/PEI-EGF) a clear 
accumulation in excised lung was observed (fig. 6 and 7). EGF-PEI caused higher 
pulmonary emission than other conjugates though 2/3 of standard PEI dose had been 
taken. In excided organs a fluorescent signal from tumor tissue was detectable 
however too weak for detection in vivo (fig. 7 and 9). To improve this signal we 
planned to perform a test using QD/PEI-EGF conjugated with PEG-shielding. 
 
 
3.2.3.2 EGF-R targeting in HUH7 Human Hepatocellular Carcinoma (II) 
 
Last experiment showed for the first time visible fluorescent signals in the excided 
tumor tissue. We tried to obtain a measurable fluorescence signal difference in vivo 
tumor and background protecting our QD/PEI-EGF conjugates with PEG. 
 
 
Animals: 5 nu/nu females, 8 weeks old; bearing HUH7 cells tumors 
 
 
Application scheme: 
 
Mice A1, A2, B2, B3    QD/PEI-EGF-PEG 
      
Mouse B1 (ctrl)    not treated     
 
 
Particles size was measured 30 minutes after separate dilution in HBG and careful 
mixing of the reagents. 
 
QD/PEI-EGF-PEG   size: 199.5 nm 
 
This value was considered adapted for iv applications into living animals avoiding lungs 
aggregations. 
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Fig. 1a,b: fluorescent image (supine) 15 minutes and 24 hours after QD/PEI-EGF-PEG iv 
application (right and left) vs ctrl (middle). Filter ex/em: ICG/ICG. Regions of interest (liver) 
marked with red circles; n: QD/PEI-EGF-PEG=4, ctrl=1. 
 
    a: after 15 minutes 
 
 
 
     b: after 24 hours 
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Fig 2a,b: fluorescent image (left side) 15 minutes and 24 hours after QD/PEI-EGF-PEG iv 
application (right and left) vs ctrl (middle). Filter ex/em: ICG/ICG. Regions of interest (tumor) 
marked with red circles; n: QD/PEI-EGF-PEG=4, ctrl=1. 
 
   a: after 15 minutes: 
 
 
   b: after 24 hours: 
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Fig. 3: excised organs of mouse A2 (QD/PEI-EGF-PEG) 
T= thyroid; RL, LL=right, left lung; H=heart; Li=liver; Sp=spleen; Tu=tumor 
 
 
 
 
Fig. 4a,b: in vivo fluorescence imaging data 15 minutes, 1, 24 and 48 hours after iv application 
of QD/PEI-EGF-PEG conjugates vs ctrl (abdominal and tumor region). 
n: QD/PEI-EGF-PEG=4, ctrl=1. 
 
a: Abdomen: 
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b: Tumor region (left loin): 
 
 
 
 
The data showed stronger dye diffusion through the tumor tissue compared to the 
results of a prior experiment with QD/PEI-EGF (fig. 4a,b). PEG-shielding enhanced the 
accumulation of QD/PEI conjugates in the tumor tissue. Fig. 1-2a,b show optical 
differences in fluorescence emission between hepatic and tumor tissue (right down) 
between the two animals. This was probably due to inhomogeneity in tumor 
vascularization and size. Some more experience was needed to assess the positive 
impact of PEG on diffusion through tumor masses. Therefore we planned another 
comparison between QD/PEI-EGF and QD/PEI-PEG conjugates. 
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3.2.3.3 EGF-R targeting in HUH7 Human Hepatocellular Carcinoma (III) 
 
After observing the first measurable signals from tumor tissue using QD/PEI-EGF-PEG 
conjugates we aimed at verifying the positive impact of PEG-shielding comparing 
distribution and tumor targeting properties of QD/PEI-EGF and QD/PEI-PEG conjugates 
labeled with anionic quantum dots (QD). 
 
 
Animals: 9 nu/nu females, 9 weeks old; bearing HUH7 cells tumors 
 
 
Application scheme: 
 
Mice C1,C2,C3,C4    QD/PEI-EGF 
 
Mice B1,B2,B3,B4    QD/PEI-PEG 
      
Mouse A (ctrl)          
 
 
Particles size was measured 30 minutes after separate dilution in HBG buffer and 
careful mixing of the reagents.  
 
QD/PEI-EGF   size: 198.4 nm 
 
QD/PEI-PEG   size: 138.2 nm 
 
 
Mice B3 and B4 died 24 hours after the iv administration of QD/PEI-PEG conjugates. 
Mice B1 and B2 which had been administered with the same solution survived 
although (as shown in pictures below) the amount of injected conjugates that 
effectively reached the circulatory system was much greater in mice B3 and B4 due to 
the better quality of intravenous application thus suggesting effective subacute toxicity 
of QD/PEI-PEG conjugates. 
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Fig. 1: fluorescent image 15 minutes after QD/PEI-EGF iv application (C1 vs ctrl vs C2). 
Filter ex/em: ICG/ICG. Regions of interest (liver) marked with black circles. 
n: QD/PEI-EGF=4, QD/PEI-PEG=4, ctrl=1. 
 
 
Fig. 2: fluorescent image 15 minutes after QD/PEI-PEG iv application (B3 vs ctrl vs B4) 
Filter ex/em: ICG/ICG. Regions of interest (liver) marked with black circles. 
n: QD/PEI-EGF=4, QD/PEI-PEG=4, ctrl=1. 
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Fig. 3: fluorescent image of the left side 15 minutes after QD/PEI-EGF iv application (C1 vs ctrl 
vs C2). Filter ex/em: ICG/ICG. Regions of interest (tumor) marked with black circles. 
n: QD/PEI-EGF=4, QD/PEI-PEG=4, ctrl=1. 
 
 
 
Fig. 4a,b: in vivo fluorescence imaging data 15 minutes, 1, 24 and 48 hours after iv application 
of QD/PEI-EGF vs QD/PEI-PEG conjugates vs ctrl (abdominal and tumor region). 
n: QD/PEI-EGF=4, QD/PEI-PEG=4, ctrl=1. 
 
a: Abdominal region: 
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b: Tumor region (left loin): 
 
 
 
The intensity of dye diffusion through the tumor tissue was comparable to the results 
using QD/PEI-PEG-EGF conjugates in previous test. Both QD/PEI-EGF and QD/PEI-PEG 
conjugates spread within liver, spleen, thyroid and lungs in a very similar way (fig. 1,2). 
Just mouse C1 (QD/PEI-EGF) showed a stronger optical tumor signal in images taken 
after 24 and 48 hours as shown above (fig. 3). PEG-shielding positively impacted dye 
diffusion throughout the tumor tissue 1 hour after application. 
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3.2.3.4 EGF-R targeting in HUH7 Human Hepatocellular Carcinoma (IV) 
 
All fluorescence imaging data obtained using QD-labeled conjugates and polyplexes of 
the last three assays (I,II,III) performed using PEI-DNA vs PEI-EGF vs PEI-EGF-PEG vs PEI 
vs ctrl are collected and compared in graphs below, sorted on the basis of the body 
region of interest. 
 
 
Fig. 1: in vivo fluorescence imaging data from abdomen of all animals treated with: 
- Free QD   3 mice 
- QD/PEI st. dose   5 mice 
- QD/PEI-EGFP Luc  3 mice 
- QD/PEI 2/3 st. dose  3 mice 
- QD/PEI-EGF   4 mice 
- QD/PEI-PEG   4 mice 
- QD/PEI-EGF-PEG  4 mice 
- Buffering solutions (ctrl) 3 mice 
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Fig. 2: in vivo fluorescence imaging data from tumor of all animals treated with: 
- QD/PEI-EGF   4 mice 
- QD/PEI-PEG   4 mice 
- QD/PEI-EGF-PEG  4 mice 
- Buffering solutions (ctrl) 3 mice 
 
 
 
 
In vivo fluorescence emission patterns of QD/PEI, QD/PEI-EGF and QD/PEI-PEG were 
basically similar. We did not observe whole body diffusion patterns, as detected after 
application of non-conjugated quantum dots, but hepatic accumulation after 15 
minutes slowly decreasing over time, and a modest accumulation in the tumor tissue. 
Occasionally tumor specific signals were very strong and comparable to that of the 
liver (considering a region with the same surface). Slightly more intense fluorescence 
was registered after PEG-shielding. EGF-PEI conjugates caused higher pulmonary 
emission and slower decrease of lungs fluorescence 24 hours after iv injection. In 
respect of biocompatibility QD/PEI-PEG particles seemed to be more toxic than the 
others. 
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3.2.3.5 Tf-R targeting in N2a Murine Neuroblastoma 
 
N2a is the second tumor cell line, well-established for in vivo imaging, that we used. It 
over-expresses receptors for human transferrin (hTf or Tf), so that conjugates 
containing transferrin are preferentially delivered into this tissue. We planned a 
distribution and tumor targeting study of QD-labeled conjugates with PEI, PEG-PEI and 
Tf-PEG3.4-PEI mixed with PEG20-PEI (termed Tf-PEG-PEI). Our aim was defining the 
impact of transferrin on distribution properties, verifying the positive effect of PEG-
shielding of the conjugates and comparing the results obtained with those using EGF in 
HUH7 tumor cells. 
 
 
Animals: 13 nu/nu males, 5 weeks old; bearing N2a tumors 
 
 
Application scheme: 
 
Mice 1,2,3,4    QD/Tf-PEG-PEI*  
 
Mice 5,6,7,8    QD/PEG-PEI 
 
Mice 9,10,11,12   QD/Tf-PEI 
 
 
30 minutes after separate dilution in HBG and mixing of the reagents particles size was 
measured. 
 
QD/ Tf-PEG3.4-PEI/PEG20-PEI*   average size: 326 nm 
 
QD/PEG-PEI      average size: 169 nm 
 
QD/Tf-PEI      average size: 259 nm 
 
On the basis of previous experience we considered these dimensions suitable for iv 
application into living animals in order to avoid lungs entrapment. 
 
Body fluorescence emission signal was checked 15 minutes, 2, 24, and 48 hours after 
systemic injection. After 48 hours all animals were sacrificed and their livers and 
tumors were excised and checked for fluorescence emission. 
Mice 4 and 5 died 20 hours after the iv application. 
                                                 
*Repeated measurements of Tf-PEG3.4-PEI complexed with anionic QD showed very large dimensions   
(diameter>2000 nm). To obtain soluble particles, mixtures of PEG-PEI (50%) and hTf-PEG3.4-PEI (50%) 
were used and the complexes termed QD/Tf-PEG-PEI. 
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Fig. 1a,b: in vivo fluorescence emission signal 15 minutes after iv application of QD/Tf-PEG-PEI 
conjugates (left and right) vs HBG buffer (middle). Filter ex/em: ICG/ICG); n: QD/Tf-PEG-PEI =4, 
QD/PEI-PEG=4, QD/Tf-PEI=4, ctrl=1. Regions of interest marked with red circles.  
 
a: QD/Tf-PEG-PEI ventral signal: 
 
 
 
b: QD/Tf-PEG-PEI dorsal signal: 
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Fig. 2: in vivo fluorescence emission signal 15 minutes after iv application of QD/Tf-PEG-PEI 
conjugates (right) vs HBG buffer (left). Filter ex/em: ICG/ICG. 
n: QD/Tf-PEG-PEI =4, QD/PEI-PEG=4, QD/Tf-PEI=4, ctrl=1. 
 
  Left lateral image 
 
 
The image above displays the left side view of a mouse administered with QD/Tf-PEG-
PEI conjugates after successful tumor targeting. The fluorescence signal from the core 
of the hypodermic tumor mass optically reacheed the same intensity as hepatic tissue. 
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Fig. 3a,b: in vivo fluorescence emission signal 15 minutes after iv application of QD/PEG-PEI 
conjugates (left and right) vs HBG buffer (middle). Filter ex/em: ICG/ICG); n: QD/Tf-PEG-PEI =4, 
QD/PEI-PEG=4, QD/Tf-PEI=4, ctrl=1. Regions of interest marked with red circles. 
 
a: QD/PEG-PEI ventral image 
 
 
 
b: QD/PEG-PEI left side signal 
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Fig. 4a,b: in vivo fluorescence emission signal 15 minutes after iv application of QD/Tf-PEI 
conjugates (left and right) vs HBG buffer (middle); Filter ex/em: ICG/ICG); n: QD/Tf-PEG-PEI =4, 
QD/PEI-PEG=4, QD/Tf-PEI=4, ctrl=1. Regions of interest marked with red circles. 
 
a: QD/Tf-PEI ventral image 
 
 
 
b: QD/Tf-PEI left side image 
 
Doctoral Thesis by Massimo Concia                                                                                                               Results 
 
65 
 
 
Fig. 5a,b: in vivo fluorescence imaging data in photons/sec 15, 100 minutes and 24, 48, and 
hours after iv administration of QD/Tf-PEG-PEI vs QD/PEG-PEI vs QD/Tf-PEI conjugates vs ctrl 
(liver and tumor region); n: QD/Tf-PEG-PEI =4, QD/PEI-PEG=4, QD/Tf-PEI=4, ctrl=1. 
 
a: liver  
 
 
b: tumor 
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Liver fluorescence decreased 1 hour after systemic administration in comparison to 
the first measurement 15 minutes after injection. The peak of hepatic accumulation of 
QD/Tf-PEI conjugates was reached after 2-3 hours observation time and decreased 
only after 6 hour (fig. 5a). The emission of the tumor tissue of QD/PEG-PEI was much 
higher than in the other groups and gradually decreased over time (fig. 5b). This result 
was also evident in our in vivo images (fig. 3b). The other tumor masses displayed good 
emission signals as well (fig. 2, 4b). Imaging results with N2a tumors were similar to 
those with HUH7 cells. Fluorescence intensity (measured in photons/sec) was 
comparable in both groups and PEG-shielding positively impacted the results in the 
same way. We detected strong hepatic emission and an evident signal from tumor 
tissue in all groups. 
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4 Discussion 
 
 
In this study organic fluorescent dyes and quantum dots emitting in the near infrared 
(NIR) spectral region were utilized for labeling PEI-based non viral gene carriers to 
observe their bio-distribution in living mice after systemic application.  
 
 
4.1 Methodological establishments 
 
Our in vivo models consisted of nu/nu mice with subcutaneously implanted tumors. 
Initial experiments were carried out in animals with fur (Albino Jackson, A/J mice) but 
fluorescence from the abdominal organs could not be visualized with satisfying quality 
because of scattering of emitted fluorescent dye by the fur. Removing superficial hair 
was possible when implanting subcutaneous tumors into the hind leg[54] but not 
applicable to the whole mouse as this would cause unnecessary stress to the animals. 
Nu/nu mice are characterized by almost complete absence of body hair and lack the 
FOXN1 gene function, thus determining severe immunodeficiency, almost absent T cell 
production and no possibility of rejection response towards non-self antigens such as 
implanted tumor cells and tissues. These are essential requirements for implanting 
xenograft (like human HUH7 Hepatocellular Carcinoma) and tumors deriving from 
different mouse strains (N2a Murine Neuroblastoma from A/J mice), that we had 
already utilized for bioluminescence assays. FOXN1 gene disruption shows variable 
phenotypical expressivity within different animals[55] so that the time between setting 
of tumor cells and formation of tumor masses as well as velocity of tumor growth is 
variable. A partial solution to this problem is careful selection of the animals age 
(between 5 and 8 weeks) in order to minimize variability in tumor growth. Employing 
younger animals (5-6 weeks) also reduces acute toxic reactions towards PEI-based 
gene carriers[21]. 
We used two tumor cells lines, well-established for in vitro and in vivo gene targeting 
experiments. Both HUH7 and N2a cells overexpress receptors for biological molecules 
that can be included in PEI-based conjugates and polyplexes, i.e. EGF-R in HUH7 and 
Tf-R in N2a. Tumor histology and vascularization have primary impact on tumor 
targeting after systemic application. Although a broad range of tumor cell lines could 
be efficiently transfected with PEI-based systems in vitro, only a few of them were 
amendable to tumor transfection in vivo[56]: only tumor cell lines leading to tumors 
with hyper-vascularized structure and leaky vasculature were efficiently transfected 
Doctoral Thesis by Massimo Concia                                                                                                          Discussion 
 
68 
 
after systemic injection of polyplexes. We utilized N2a and HUH7 model: both tumors 
are well vascularized and exhibit leaky blood vessels. In HUH7 tumors large blood 
vessels are found and blood lakes can be observed. In N2a necrotic cores are present 
when tumors exceed volume of approximately 0.9 cm3. 
The application of many fluorescent dyes for in vivo imaging is limited by light 
absorption by abundant components like hemoglobin in blood and chlorophyll 
contained in the animals feeding, where the latter also emits within the near infrared 
range. The choice of hairless animals and proper adjustments in image exposure and 
analysis to eliminate background fluorescence significantly improved the signal-to-
noise ratio. The quality of fluorescence signal was further improved by feeding our 
nu/nu mice with chlorophyll-free mouse chow in order to diminish abdominal auto-
fluorescent phenomena.  
The biodistribution of fluorescently labeled gene carriers or free dyes was mostly 
visualized 15 minutes, 120 minutes, 24 hours and 48 hours after the intravenous 
administration of them. Diffusion throughout the mouse organism, organ 
accumulation (i.e. in liver, lungs and thyroid) and renal excretion were observed 15 
and 120 min after injection. The observation after 24 hours seemed to be the time 
point adapted for checking tumor tissue specific accumulation. After 48 hours the 
signal decreased in all organs and body compartments including the tumor masses. 
The excision and ex vivo analysis of tumor tissue gave additional information on dye 
accumulation in the tumors: unlike the organs, which mostly display homogenous 
parenchymal diffusion of the fluorescent dyes, tumors were often only superficially 
vascularized and the necrotic core of many masses was not involved in drug diffusion 
due to the lack of functional blood vessels. 
All fluorescent images were taken using ICG/ICG (excitation/emission wavelength of 
indocyanine green) filter combination because unspecific emissions are not present in 
this region (see 1.5.2). Fluorescence signal data were mostly edited as total flux 
(photons/sec; see 2.6.1) and compared utilizing a standardized “region of interest” 
(ROI) surface and identical color bar scales for images to be compared. 
We used mostly brPEI25 (branched polyethylenimine, 25 kDa) in biodistribution 
experiments, sometimes as a block-copolymer with PEG. In general low 
acute/subacute toxicity was observed: most of the animals survived apparently 
without severe symptoms the first days after iv injection of PEI-based conjugates. 
Pulmonary erythrocyte aggregation induced by positively charged PEI is described in 
the literature[21]. Acute/subacute mortality rate between 25 and 30 % was observed in 
some preliminary assays, we had performed using NIR 797/brPEI25-mEGF conjugates 
and 15-20% with QD/brPEI25-PEG and QD/brPEI25-Tf conjugates. This was most likely 
due to the age of the animals (>8 weeks) and particles aggregation prior to injection 
caused by improper particle mixing. Hence all particle preparations were analyzed 
prior to administration in vivo in following experiments. An average particle diameter 
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<250 nm was considered suitable for in vivo without inducing mortality. The size of PEI 
aggregate itself is a very important factor causing toxicities additional to intrinsic PEI 
toxicity. Similar observations were made by Wightman et al[57], where aggregated 
polyplexes larger than 200 nm exhibited more pronounced toxicities than small 
particles. In the current study similar effects were observed when applying aggregates 
of PEI with QD. In order to prevent aggregate formation PEI was mixed with QD in a 
low salt buffer (HEPES-buffered saline, HBG) reducing aggregate formation. No death 
cases were observed in animals groups treated with Alexa 750/HD O thanks to reduced 
particle dimensions of this conjugate. This is in line with OEI and HD O low toxicity 
reported in a recent article[21]. 
 
 
4.2 Fluorescence-based in vivo imaging 
 
4.2.1 Fluorescent dyes (Alexa 750 and NIR 797) applications 
 
Alexa Fluor® 750 carboxylic acid, succinimidyl ester is a fluorescent dye suitable for in 
vivo imaging: it has an amino reactive succinimidyl ester group which enables covalent 
bonding to primary amino groups of the PEIs. The spectral features (ex/em: 749/775 
nm) of this dye make it adapted for applications in the near infrared spectrum, least 
disturbed by non-specific autofluorescence. Alexa 750 was first administered as free 
dye and then utilized to label brPEI25 and HD O (OEI core modified with hexane-1,6-
diol diacrylate and OEI). Fifteen minutes after the injection of “free” Alexa 750 a clear 
signal throughout the whole organism and particularly in bladder, thyroid and liver was 
detected, where highest signal intensities were measured. When coupled to branched 
PEI25 or H DO the distribution pattern was clearly different: fluorescence was detected 
in lungs and liver which corresponds to the distribution patterns of positively loaded 
polycations when interacting with negatively charged erythrocytes and body cell 
surfaces. The pulmonary accumulation was lower than the hepatic one and 
acute/subacute toxicity due to lungs embolism seldom occurred. Hence Alexa 750 is a 
well suited fluorescent dye for labeling vectors like PEIs. Disadvantages are its very 
high cost and unpublished chemical structure. 
 
NIR 797 isothiocyanate has spectral and chemical features adapted for in vivo imaging 
purposes. Excitation/emission (795/835 nm) maxima are within the NIR region and the 
isothiocyanate group allows covalent bonding to primary amines. When “free” injected 
at the same dose of Alexa 750 a strong hepatic fluorescence was detected. Unlike 
Alexa 750 NIR 797 tended to accumulate within the liver and scarcely in thyroid and 
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lungs. The signal intensity was somehow lower than Alexa 750, but the product is 
cheaper than Alexa 750 and its molecular structure is known. 
 
4.2.2 Quantum dots applications 
 
All quantum dot formulations that we tested were synthesized by Dr Andrei Susha in 
the Photonics and Optoelectronics Work Group led by Dr Andrey Rogach at the LMU, as 
recently described in the literature[58]. We tested quantum dots with different surface 
modifications and finally selected as standard anionic QD with Cd-Te core, S-C3H6-
COO- groups on the surface and average size of 7 nm. Their fluorescence emission 
properties (ex/em: 500-550/750-800 nm) were compatible with our standard setup 
and they gave a bright fluorescent signal after illumination. After systemic 
administration QD widely diffused through the body compartments and fluids 
including bone marrow, skin, joints and salivary glands, partially reproducing the 
diffusion pattern observed with other small particles like fluorescently labeled OEI (HD-
O). In order to reduce acute toxicity of QD/PEI particles, we standardized the mixture 
modalities, avoiding formation of aggregates after complexing. We verified that a strict 
control of particle dimensions considerably reduced mortality. In further experiments 
QD/PEI conjugates containing murine EGF (mEGF) or human transferrin (hTf), with or 
without PEG-shielding, were used for tumor targeting studies in HUH7 or N2a tumor 
bearing animals.  
 
 
4.3 Conclusions 
 
We assessed that PEI is a very suitable device for low-invasive in vivo transfection of 
tumor cells in rodents. Our findings showed that QD are cheap and reliable fluorescent 
markers. They were the best method of labeling PEI-based gene therapy vectors in our 
experience[59]. QD displayed much stronger fluorescence at lower concentrations than 
organic dyes (Alexa 750 and NIR 797) and enabled low-cost experiments. In addition 
their inorganic structure can be easily modified and adapted to several experimental 
or clinical issues; they are low toxic and are designed and produced by a partner 
laboratory. 
EGF and Tf enabled selective targeting of tumor cell lines expressing specific receptors 
for these molecules. Their integration into fluorescently labeled PEI-based conjugates 
and polyplexes positively impacted tumor targeting and enhanced fluorescent signal 
from tumor tissue.  
We got the best results using QD/PEI-EGF and QD/PEI-Tf conjugates in HUH and N2a 
cell tumors in vivo. PEG-shielding displayed in both cases a positive impact on tumor 
targeting. A clear fluorescent signal specific for tumor tissue was detected; the imaging 
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software used allowed quantitative analysis of this signal. These are the best devices 
for fluorescent labeled gene vectors in our experience. 
In the literature[25][26][27][28] optical imaging methods are often compared with other 
imaging technologies like micro-PET, CT and MR. Controlling systems of gene delivering 
based on fluorescent methods enable easy application and measurement procedures, 
minor costs and no use of radiotracers or waiting for decay times. They require 
furthermore shorter scanning times and many animals can be analyzed 
simultaneously. Compared to PET however, they deliver semi-quantitative results and 
minor depth of analysis. In addition signals are often confounded by intrinsic 
fluorescence of biomelocules. PET and MR moreover offer quantitative analysis and 
tomographic images, easily transferable to clinical applications. Obtaining quantitative 
and reproducible informations is then a major issue for optical i.e. fluorescence and 
bioluminescence methods.  
Future in vivo experiments with QD-labeled PEI-EGF or PEI-transferrin conjugates or 
polyplexes with PEG-shielding performed by our research group should focus on 
reproducibility, statistical relevance and standardizing all experimental procedure 
conditions. 
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5a Summary 
 
Gene therapy is a research area where nucleic acids are transferred into cells to treat 
neoplastic, metabolic and hereditary diseases. Delivery of genetic material into living 
organisms can be achieved with viral or non-viral vectors. Viral gene carriers are very efficient 
but present some major disadvantages due to their pathogenicity and immunogenicity. Non-
viral carriers are based on synthetic molecules binding and condensing nucleic acids into small, 
virus-like particles. The aim of this thesis was to study the biodistribution and tumor 
targeting properties of non-viral gene vectors based on polyethylenimine (PEI) after systemic 
injection into mice. The gene vectors were labeled with fluorescent dyes emitting in the near 
infrared (NIR), which allowed studying their bio-distribution in living animal over time. Owing 
to its amine groups PEI has a high positive charge density that enables electrostatic 
interactions with negatively charged nucleic acids and their efficient compaction into nucleic 
acid-PEI complexes, called polyplexes. The net positive surface charge of these polyplexes 
permits interactions with negatively charged cell surface molecules, thus leading to their 
internalization into the cell. To avoid unspecific interactions with blood components and non-
target tissues after intravenous application, polyplexes were shielded with the hydrophilic 
molecule polyethylene glycol (PEG). PEI-based gene carrier systems were tested on two 
subcutaneously implanted tumor types: Human Hepatocellular Carcinoma (HUH7) and Murine 
Neuroblastoma (N2a). HUH7 cells express epidermal growth factor (EGF) receptors, while N2a 
cells express transferrin (Tf) receptors on their surfaces. To enable targeting of the polyplexes 
to the tumor cells, polyplexes were generated containing the ligands EGF and Tf for targeting 
of HUH7 cells and N2a cells respectively. The targeted polyplexes were then intravenously 
injected into immunodeficient, athymic nu/nu mice in which HUH7 or N2a tumor cells had 
been previously set under their skin. To monitor the biodistribution of polyplexes throughout 
the mouse organism and to evaluate their gene delivery capability into the neoplastic cells, 
polyplexes were labeled with fluorescent dyes (Alexa 750, NIR 797) or near infrared emitting 
quantum dots (QD), whose fluorescent expression signal was detected and analyzed with a 
device for imaging in vivo. All fluorescent molecules and quantum dots were biocompatible 
and non-toxic. They emitted light in the near infrared area of the spectrum, thus avoiding 
overlapping phenomena with autofluorescent biomolecules or absorption of light by 
hemoglobin. With all dyes used for polyplex labeling a fluorescent signal could be observed in 
organs like liver and lung being clearly distinguishable from background fluorescence. Among 
the fluorescent molecules tested, quantum dots were identified being the most suitable 
method for in vivo studies, showing the highest signal/noise ratios. PEG-shielding led to best 
tumor targeting efficiency when administering EGF or Tf-targeted polypelxes in mice bearing 
HUH7 and N2a tumors respectively. A clear fluorescent signal specific for tumor tissue was 
detected; the imaging software used allowed quantitative analysis of this signal. For this 
reason this system is now available for further experimental applications. 
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5b Zusammenfassung 
 
Gentherapie befasst sich mit der Insertion von Nukleinsäuren in Zellen, um neoplastische, 
metabolische sowie hereditäre Krankheiten zu behandeln. Der Transfer von genetischem 
Material in einen lebenden Organismus kann durch die Verwendung viraler oder nicht viraler 
Vektoren erfolgen. Viren sind zwar sehr effektiv, aber ihre Anwendung birgt auch Probleme, die 
meist durch ihre Pathogenität und Immunogenität bedingt sind. Nicht virale Vektoren sind 
synthetische Moleküle, die Nukleinsäuren in kleine, virusähnliche Partikeln einbinden und 
kondensieren. Das Ziel dieser Doktorarbeit war es die Bioverteilung und die gezielt gegen den 
Tumor gerichteten Eigenschaften von Genvektoren, die auf Polyethylenimin (PEI) basieren, 
nach intravenöser Injektion in Mäusen zu untersuchen.  
Die Genvektoren wurden mit fluoreszierenden Farbstoffen markiert, die Licht innerhalb des 
Nahinfrarot-Bereiches (NIR) emittieren und im Zeitverlauf die Beobachtung der Bioverteilung in 
lebenden Tieren erlauben. Dank seiner Aminogruppen hat PEI eine stark positive Ladung, die 
gute elektrostatische Bindungen zu negativ geladenen Nukleinsäuren erlaubt, mit denen es zum 
Aufbau eines Nukleinsäure-PEI-Komplexes führt, der Polyplex genannt wird. Die positiv geladene 
Oberfläche von PEI ermöglicht auch Interaktionen mit negativ geladenen Zellenoberflächen mit 
der Folge einer Internalisierung des Komplexes. Um unspezifische Interaktionen mit 
Blutbestandteilen oder anderen als dem Zielgewebe zu verhindern, wurden die Polyplexe mit 
dem hydrophilen Molekül Polyethylenglycol (PEG) umhüllt. Diese auf PEI-Basis synthetisierten 
Gencarrier-Systeme wurden dann an der humanen Leberzell Karzinom Linie HUH7 und der Maus 
Neuroblastom Linie N2a getestet. Die HUH7-Zellinie exprimiert Rezeptoren für den epidermalen 
Wachstumsfaktor (EGF) und die N2a-Zelllinie Rezeptoren für Transferrin (Tf) auf ihrer Oberfläche. 
Um ein gezieltes Tumor-Targeting von HUH7- oder N2a-Zellen zu ermöglichen, wurden Polyplexe 
erstellt, die EGF bzw. Transferrin an ihrer Oberfläche enthalten. Diese oberflächlich modifizierten 
Komplexe wurden dann intravenös in athymische nu/nu Mäuse verabreicht, die vorher HUH7- 
oder N2a-Zellen subkutan implantiert bekommen hatten. Um die Verteilung der Polyplexe als 
experimentelle genetische Medikamente innerhalb des murinen Organismus zu beobachten und 
die Akkumulation im Tumorgewebe auszumessen, waren sie mit fluoreszierenden Farbstoffen 
(Alexa 750, NIR 797) oder im Nahinfraroten emittierenden Quantum Dots (QD) markiert, deren 
Fluoreszenzsignalexpression mittels eines Messungsgerät für in vivo Analysen analysiert wurde.  
Alle fluoreszierenden Moleküle und Quantum Dots zeigten sich biokompatibel und nicht toxisch 
und emittierten Licht innerhalb des nahinfraroten Bereichs des Spektrums. Damit konnte die 
Lichtabsorption durch Hämoglobin ebenso vermieden werden, wie sämtliche Überschneidungs-
phänomene mit der Fluoreszenz anderer Biomoleküle. Bei allen für die Markierung von 
Polyplexen verwendeten Farbstoffen und den Quantum Dots wurde ein fluoreszierendes Signal in 
Organen wie Leber und Lunge beobachtet, das eindeutig von der Hintergrundfluoreszenz 
unterschieden werden konnte. Unter den getesteten fluoreszierenden Substanzen konnten 
Quantum Dots als beste Methode für die Fluoreszenzmarkierung festgelegt werden. Hier war das 
Signal am deutlichsten von störender Hintergrundstrahlung zu unterscheiden. Das PEG-Shielding 
erlaubte die höchste Effizienz im Tumor-Targeting vor allem bei Applikation von EGF- bzw. Tf-
markierten Polyplexen in Mäusen, die HUH7- bzw. den N2a-Tumor trugen. Ein ausgeprägtes und 
für Tumorgewebe spezifisches Signal konnte hier beobachtet werden. Die verwendete Imaging-
Software für in vivo Applikationen ermöglichte eine quantitative Signalanalyse. Damit steht 
dieses System für weitere experimentelle Anwendungen zur Verfügung. 
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6 Appendix 
 
 
6.1 Abbreviations 
 
 
brPEI, bPEI  branched polyethylenimine 
ctrl   control 
Cy   cyanine  
DMSO   dimethyl sulfoxide 
EDTA   ethylendiamin tetracetic acid 
EGF   epithelial growth factor 
EtBr   ethidium bromide  
FACS    fluorescent-activated cell sorting 
FCS   fetal calf serum 
GFP   green fluorescent protein 
HBG   HEPES-buffered glucose 
HBS   HEPES-buffered saline 
HCl   hydrochloric acid 
HD O   OEI core modified with hexane-1,6-diol diacrylate and OEI  
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hTf   human transferrin 
HUH7   Human Hepatocellular Carcinoma HuH7 
ICG   indocyanine green 
iv   intravenous 
mEGF   murine epithelial growth factor 
MRI   magnetic resonance imaging 
mRNA   messenger RNA 
Mw   molecular weight 
N/P ratio  molar ratio of PEI nitrogen to DNA phosphate 
N2a   Murine Neuroblastoma N2a 
NaCl   sodium chloride 
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NIR   near-infrared 
OEI   oligoethylenimine 
PBS   phosphate-buffered saline 
PEG   polyethylene glicole 
PEI   polyethylenimine 
PEI lin, lnPEI  linear polyethylenimine 
PET   positron emission tomography 
QD   quantum dots 
ROI   region of interest 
RT   room temperature 
siRNA   small interfering RNA 
SPECT   single photon emission tomography 
Tf   transferrin 
TBE   tris-borate EDTA 
TNBS   trinitrobenzesulphonic acid assay 
vs   versus
Doctoral Thesis by Massimo Concia                      Acknowledgments 
 
76 
 
 
 
7 Acknowledgments 
 
 
I am very grateful to Prof. Georg Enders for presenting my work to the Faculty of Medicine of 
the LMU, for his precious advice and his great helpfulness. 
 
 
Many thanks to Prof. Ernst Wagner for giving me the opportunity of working in his research 
group and his fair way of motivating and supporting our scientific activity. 
 
 
Without Dr. Manfred Ogris, who helped me with his great experience in fluorescence 
imaging and in vivo assays, this work would not have been possible. I thank him sincerely for 
his great scientific competence, his humor and patience, his kind way of being an example 
for all of us. 
 
 
Many thanks go also to Dr. Arkadi Zintchenko for his indispensable assistance in synthesis 
and analysis of our gene vectors. 
 
 
To all technical assistants of the Workgroup Wagner at the Department of Pharmacy for 
their help and sympathy, thank you! 
 
 
 
Thank you for everything and forever  
 
 
 
 
Grazie per tutto, e per sempre … 
 
 
Doctoral Thesis by Massimo Concia                      References 
 
77 
 
 
                                                 
 
 
8  References 
 
 
 
 
1
 Wagner E. 
Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA 
nucleic acids. 
J BUON. 2007 Sep;12 Suppl 1:S77-82. Review. 
 
2 Ogris M. 
Nucleic acid based therapeutics for tumor therapy. 
Anticancer Agents Med Chem. 2006 Nov;6(6):563-70. Review.  
 
3 Meyer M, Wagner E. 
Recent developments in the application of plasmid DNA-based vectors and small interfering RNA 
therapeutics for cancer. 
Hum Gene Ther. 2006 Nov;17(11):1062-76. Review. 
 
4 Whitehead KA, Langer R, Anderson DG. 
Knocking down barriers: advances in siRNA delivery. 
Nat Rev Drug Discov. 2009 Feb;8(2):129-38. 
 
5
 Gao K, Huang L. 
Nonviral Methods for siRNA Delivery. 
Mol Pharm. 2008 Dec 30. Review. 
 
6 Robbins PD, Ghivizzani SC. 
Viral vectors for gene therapy. 
Pharmacol Ther. 1998 Oct;80(1):35-47. Review. 
 
7 Damjanovic D, Zhang X, Mu J, Medina MF, Xing Z. 
Organ distribution of transgene expression following intranasal mucosal delivery of recombinant 
replication-defective adenovirus gene transfer vector. 
Genet Vaccines Ther. 2008 Feb 8;6(1):5  
 
8 Beard BC, Keyser KA, Trobridge GD, Peterson LJ, Miller DG, Jacobs M, Kaul R, Kiem HP. 
Unique integration profiles in a canine model of long-term repopulating cells transduced with 
gammaretrovirus, lentivirus, or foamy virus. 
Hum Gene Ther. 2007 May;18(5):423-34. 
 
9 Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X, Chu CR. 
Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal 
stem cells improves cartilage repair. 
Gene Ther. 2007 May;14(10):804-13. Epub 2007 Mar 8.  
 
Doctoral Thesis by Massimo Concia                      References 
 
78 
 
                                                                                                                                                        
10 Hassan MH, Khatoon N, Curiel DT, Hamada FM, Arafa HM, Al-Hendy A. 
Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells. 
Hum Reprod. 2008 Jan 8. 
 
11 Mancheño-Corvo P, Martín-Duque P. 
Viral gene therapy. 
Clin Transl Oncol. 2006 Dec;8(12):858-67. 
 
12 Simões S, Filipe A, Faneca H, Mano M, Penacho N, Düzgünes N, de Lima MP. 
Cationic liposomes for gene delivery. 
Expert Opin Drug Deliv. 2005 Mar;2(2):237-54.  
 
13 Hassani Z, Lemkine GF, Erbacher P, Palmier K, Alfama G, Giovannangeli C, Behr JP, Demeneix BA. 
Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at 
picomolar levels. 
J Gene Med. 2005 Feb;7(2):198-207. 
 
14 Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine. 
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301. 
 
15 Demeneix B, Behr JP. 
Polyethylenimine (PEI). 
Adv Genet. 2005;53PA:215-230. 
 
16 Kopatz I, Remy JS, Behr JP. 
A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. 
J Gene Med. 2004 Jul;6(7):769-76. 
 
17 Erbacher P, Bettinger T, Belguise-Valladier P, Zou S, Coll JL, Behr JP, Remy JS. 
Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-
derivatized polyethylenimines (PEI). 
J Gene Med. 1999 May-Jun;1(3):210-22.  
 
18 Park MR, Kim HW, Hwang CS, Han KO, Choi YJ, Song SC, Cho MH, Cho CS. 
Highly efficient gene transfer with degradable poly(ester amine) based on poly(ethylene glycol) 
diacrylate and polyethylenimine in vitro and in vivo. 
J Gene Med. 2008 Feb;10(2):198-207. 
 
19 Zhang XQ, Intra J, Salem AK. 
Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles 
prepared using double emulsion methods. 
J Microencapsul. 2008 Feb;25(1):1-12. 
 
20 Kunath K, von Harpe A, Petersen H, Fischer  D, Voigt K, Kissel Z, Bickel U. 
The Structure of PEG-Modified Poly(Ethylene Imines) Influences Biodistribution and 
Pharmacokinetics of Their Complexes with NF-kB Decoy in Mice. 
Pharmaceutical Research, Vol. 19, No. 6, June 2002 (© 2002). 
 
 
Doctoral Thesis by Massimo Concia                      References 
 
79 
 
                                                                                                                                                        
21
 Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. 
Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. 
J Gene Med. 2004 Oct;6(10):1102-11. 
 
22 Chollet P, Favrot MC, Hurbin A, Coll JL. 
Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. 
J Gene Med. 2002 Jan-Feb;4(1):84-91. 
 
23 Sharma VK, Thomas M, Klibanov AM. 
Mechanistic studies on aggregation of polyethylenimine-DNA complexes and its prevention. 
Biotechnol Bioeng. 2005 Jun 5;90(5):614-20. 
 
24 Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. 
PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended 
circulation in blood and potential for systemic gene delivery. 
Gene Ther. 1999 Apr;6(4):595-605. 
 
25
 Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. 
Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo 
gene transfer. 
Gene Ther. 2008 Jan;15(1):18-29. Epub 2007 Oct 25. 
 
26 Kristian Räty J, Liimatainen T, Unelma Kaikkonen M, Gröhn O, Jumani Airenne K, Ylä-Herttuala S. 
Non-invasive Imaging in Gene Therapy. 
Mol Ther. 2007 Sep;15(9):1579-86. Epub 2007 Jun 19. Review. 
 
27 Belmar C, So PW, Vassaux G, Moleiro-Sanemeterio V, Martín-Duque P. 
Non-invasive genetic imaging for molecular and cell therapies of cancer. 
Clin Transl Oncol. 2007 Nov;9(11):703-14. 
 
28 Winkeler A, Sena-Esteves M, Paulis LE, Li H, Waerzeggers Y, Rückriem B, Himmelreich U, Klein M, 
Monfared P, Rueger MA, Heneka M, Vollmar S, Hoehn M, Fraefel C, Graf R, Wienhard K, Heiss WD, 
Jacobs AH. 
Switching on the lights for gene therapy. 
PLoS ONE. 2007 Jun 13;2(6):e528. 
 
29 Doubrovin M, Serganova I, Mayer-Kuckuk P, Ponomarev V, Blasberg RG. 
Multimodality in vivo molecular-genetic imaging. 
Bioconjug Chem. 2004 Nov-Dec;15(6):1376-88. 
 
30 Rao J, Dragulescu-Andrasi A, Yao H. 
Fluorescence imaging in vivo: recent advances. 
Curr Opin Biotechnol. 2007 Feb;18(1):17-25. Epub 2007 Jan 17. Review. 
 
31  D. C. Prasher, V. K. Eckenrode, W. W. Ward, F. G. Prendergast, M. J. Cormier 
Primary structure of the Aequorea victoria green-fluorescent protein. 
Gene. Band 111, 1992, S. 229-233. 
 
32 Bucci E, Malak H, Fronticelli C, Gryczynski I, Laczko G, Lakowicz JR. 
Time-resolved emission spectra of hemoglobin on the picosecond time scale. 
Biophys Chem. 1988 Dec;32(2-3):187-98. 
Doctoral Thesis by Massimo Concia                      References 
 
80 
 
                                                                                                                                                        
33 
Detter C, Wipper S, Russ D, Iffland A, Burdorf L, Thein E, Wegscheider K, Reichenspurner H, 
Reichart B. 
Fluorescent cardiac imaging: a novel intraoperative method for quantitative assessment of 
myocardial perfusion during graded coronary artery stenosis. 
Circulation. 2007 Aug 28;116(9):1007-14. Epub 2007 Aug 7. 
 
34 Koyama T, Tsubota A, Nariai K, Mitsunaga M, Yanaga K, Takahashi H. 
Novel biomedical imaging approach for detection of sentinel nodes in an experimental model of 
gastric cancer. 
Br J Surg. 2007 Aug;94(8):996-1001. 
 
35 Alacam B, Yazici B, Intes X, Nioka S, Chance B. 
Pharmacokinetic-rate images of indocyanine green for breast tumors using near-infrared optical 
methods. 
Phys Med Biol. 2008 Feb 21;53(4):837-59. Epub 2008 Jan 15. 
 
36
 Unno N, Suzuki M, Yamamoto N, Inuzuka K, Sagara D, Nishiyama M, Tanaka H, Konno H. 
Indocyanine green fluorescence angiography for intraoperative assessment of blood flow: a 
feasibility study. 
Eur J Vasc Endovasc Surg. 2008 Feb;35(2):205-7. Epub 2007 Oct 26. 
 
37 Wakaiki S, Maehara S, Abe R, Tsuzuki K, Igarashi O, Saito A, Itoh N, Yamashita K, Izumisawa Y. 
Indocyanine green angiography for examining the normal ocular fundus in dogs. 
J Vet Med Sci. 2007 May;69(5):465-70.  
 
38 Hoshino A, Manabe N, Fujioka K, Suzuki K, Yasuhara M, Yamamoto K. 
Use of fluorescent quantum dot bioconjugates for cellular imaging of immune cells, cell organelle 
labeling, and nanomedicine: surface modification regulates biological function, including cytotoxicity. 
J Artif Organs. 2007;10(3):149-57. Epub 2007 Sep 20. Review. 
 
39 Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV. 
Renal clearance of quantum dots. 
Nat Biotechnol. 2007 Oct;25(10):1165-70. Epub 2007 Sep 23. 
 
40 Ballou B, Ernst LA, Andreko S, Harper T, Fitzpatrick JA, Waggoner AS, Bruchez MP. 
Sentinel lymph node imaging using quantum dots in mouse tumor models. 
Bioconjug Chem. 2007 Mar-Apr;18(2):389-96. Epub 2007 Jan 31. 
 
41 Iga AM, Robertson JH, Winslet MC, Seifalian AM. 
Clinical potential of quantum dots. 
J Biomed Biotechnol. 2007;2007(10):76087. 
 
42 Pietryga JM, Werder DJ, Williams DJ, Casson JL, Schaller RD, Klimov VI, Hollingsworth JA. 
Utilizing the Lability of Lead Selenide to Produce Heterostructured Nanocrystals with Bright, Stable 
Infrared Emission. 
J Am Chem Soc. 2008 Mar 15; 
 
43 Ogris M, Wagner E. 
Tumor-targeted gene transfer with DNA polyplexes. 
Somat Cell Mol Genet. 2002 Nov;27(1-6):85-95. Review. 
 
Doctoral Thesis by Massimo Concia                      References 
 
81 
 
                                                                                                                                                        
44 Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. 
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-
polyethylenimine/DNA complexes. 
J Control Release. 2003 Aug 28;91(1-2):173-81. 
 
45 Kursa M, Walker GF, Roessler V, Ogris M, Roedl W, Kircheis R, Wagner E. 
Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-
targeted gene transfer. 
Bioconjug Chem. 2003 Jan-Feb;14(1):222-31. 
 
46 Kircheis R, Wightman L, Schreiber A, Robitza B, Rössler V, Kursa M, Wagner E. 
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after 
systemic application. 
Gene Ther. 2001 Jan;8(1):28-40. 
 
47 Wolschek MF, Thallinger C, Kursa M, Rössler V, Allen M, Lichtenberger C, Kircheis R, Lucas T, 
Willheim M, Reinisch W, Gangl A, Wagner E, Jansen B. 
Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. 
Hepatology. 2002 Nov;36(5):1106-14. 
 
48
 Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E. 
Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted 
gene delivery. 
Bioconjug Chem. 2001 Jul-Aug;12(4):529-37. 
 
49 Zintchenko A, Konák C. 
Interaction of DNA/polycation complexes with phospholipids: stabilizing strategy for gene delivery. 
Macromol Biosci. 2005 Dec 15;5(12):1169-74. 
 
50 Zintchenko A, Ogris M, Wagner E. 
Temperature dependent gene expression induced by PNIPAM-based copolymers: potential of 
hyperthermia in gene transfer. 
Bioconjug Chem. 2006 May-Jun;17(3):766-72. 
 
51 Zintchenko A, Konák C. 
Interaction of DNA/polycation complexes with phospholipids: stabilizing strategy for gene delivery. 
Macromol Biosci. 2005 Dec 15;5(12):1169-74. 
 
52 Zintchenko A, Ogris M, Wagner E. 
Temperature dependent gene expression induced by PNIPAM-based copolymers: potential of 
hyperthermia in gene transfer. 
Bioconjug Chem. 2006 May-Jun; 17(3):766-72. 
 
53 Fahrmeir J, Gunther M, Tietze N, Wagner E, Ogris M. 
Electrophoretic purification of tumor-targeted polyethylenimine-based polyplexes reduces toxic side 
effects in vivo 
Journal of Controlled Release. 2007 Oct; 122(3):236-245. 
 
54 Schwerdt A, Zintchenko A, Concia M, Roesen N, Fisher KD, Lindner LH, Issels RD. 
Hyperthermia induced targeting of thermosensitive gene carriers to tumors. 
Hum Gene Ther. 2008 Aug 26. 
Doctoral Thesis by Massimo Concia                      References 
 
82 
 
                                                                                                                                                        
55 Fogh J; Giovanella M. 
The Nude Mouse in Experimental and Clinical Research (Vol.1) 
Academic Press, 1978. 
 
56 Smrekar B, Wightman L, Wolschek MF, Lichtenberger C, Ruzicka R, Ogris M, Rödl W, Kursa M, 
Wagner E, Kircheis R. 
Tissue-dependent factors affect gene delivery to tumors in vivo. 
Gene Ther. 2003 Jul;10(13):1079-88. 
 
57 Wightman L, Kircheis R, Rössler V, Carotta S, Ruzicka R, Kursa M, Wagner E. 
Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. 
J Gene Med. 2001 Jul-Aug;3(4):362-72. 
 
58 Rogach AL. 
Aqueous synthesis of thiol-capped CdTe nanocrystals: State-of-the-art.  
Journal of Physical Chemistry C 111(2007): 14628-14637. 
 
59 Zintchenko A, Susha AS, Concia M, Feldmann J, Wagner E, Rogach AL, Ogris M. 
Drug Nanocarriers Labeled With Near-infrared-emitting Quantum Dots (Quantoplexes): Imaging Fast 
Dynamics of Distribution in Living Animals. 
Mol Ther. 2009 Aug 25. 
